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Abstract
English
The regulation of glucose metabolism, in healthy subjects, is based on a
complex control system which aims to maintain plasma glucose concentra-
tions within a narrow range (70÷180 mg/dl). Insulin, a hormone secreted
by pancreatic beta-cells, is fundamental in maintaining glucose homeostasis,
by reducing liver glucose production, while promoting its utilization by the
insulin-dependent organs. The inability of beta-cells to adequately secrete
insulin creates metabolic disorders which can result in glucose intolerance
and even diabetes mellitus. There are two different kinds of diabetes: type 1
diabetes (T1DM), characterized by a total inability of pancreatic beta-cells
to secrete insulin, and type 2 diabetes (T2DM), in which, because of insulin
resistance, tissues are unable to appropriately utilize glucose, and insulin
secretion is unable to compensate for this defect. Given the increasing pre-
valence of diabetes, a complete understanding of all the mechanisms involved
in the glucose regulation system is essential.
The liver is a fundamental organ in glucose regulation, since it is also
responsible for circulating insulin levels by extracting about 50% of insulin
appearing in the portal circulation, with every passage through it. A quant-
itative estimation of hepatic insulin extraction (HE), both in basal and dy-
namic physiological conditions (such as after an oral glucose load) is therefore
a key aspect for a systematic description of glucose metabolism. Since a dir-
ect measurement of HE is very invasive, requiring the insertion of catheters
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into the portal and hepatic veins, indirect methods employing mathematical
models are used. Such models require measurement of plasma concentrations
and knowledge of the kinetics of C-peptide, and insulin secretion and clear-
ance. This is facilitated by the fact that insulin and C-peptide are secreted
in a 1:1 ratio by the beta-cells, and that the liver extracts insulin, but not
C-peptide.
The first model available in the literature for assessing HE was developed
by Toffolo et al. and describes HE during an insulin modified intravenous
glucose tolerance test (IM-IVGTT); this model estimates the insulin secre-
tion rate (ISR) and the insulin delivery rate (IDR) from C-peptide and in-
sulin concentrations, respectively. HE is subsequently derived from these two
fluxes. More recently, Campioni et al. proposed a model to estimate HE after
meal ingestion. In this case HE is described as a piecewise linear function,
with a fixed number of breakpoints, which are the model parameters to be
estimated. The main limitation of this approach is that, although allowing a
reconstruction of the HE profile, it does not provide a mechanistic relation-
ship between the involved variables, and thus the resulting model parameters
do not have an easy physiological interpretation. Moreover, model structure
makes the parameter identification vulnerable to noise, since the HE profile
may vary rapidly to fit fluctuations in peripheral insulin concentrations.
The aim of this work is to overcome the disadvantages of the available
HE description by proposing a new physiological model of insulin kinetics
and extraction. The best model is selected from seven, including an in-
creasing number of compartments and different mechanistic descriptions of
HE, each taking into account the influence of one or more modifiers, such
as plasma glucose and insulin concentrations. In fact, during an oral test,
one observes that, while glucose and insulin concentrations rise, the HE time
course decreases in the meantime. These models are tested against data of a
frequently sampled mixed meal (21 plasma samples) measured in 204 healthy
subjects. The best model was selected according to standard criteria (ability
to describe the data, precision of parameter estimates, model parsimony).
Such a model describes insulin kinetics with three compartments, and HE
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as a function of plasma glucose concentration. One of the peculiarities of
this model is to provide an index of HE sensitivity to glucose (SHEG ), besides
total (HEtot) and basal (HEb) HE indexes, already adopted in the literature.
Moreover, the new model performs well even in data sets with less frequent
sampling (11 samples).
The new model was then applied to three further databases, involving
subjects with different degrees of glucose tolerance, studied with a standard
mixed meal or the oral glucose tolerance test (OGTT). The first data set
is composed of 62 prediabetic subjects (including healthy, glucose intolerant
subjects, and subjects with impaired fasting glucose), who underwent a triple
tracer mixed meal and an OGTT. The model was able to describe data
during both the tests, and HE indexes are shown to correlate with the degree
of dysfunction in glucose metabolism. The second data set consists of 11
healthy and 14 T2DM subjects, matched for age, weight and body mass index
(BMI), who underwent a mixed meal test with the triple tracer technique.
Also in this case, the new model predicts the data, and the estimated HE
indexes (HEb, HEtot, SHEG ) differ significantly between the two groups. The
last database is composed of 14 subjects with T2DM who were treated with
vildagliptin or placebo before the meal; moreover, at t = 300 min, 0.02
unit/kg insulin was administered intravenously (over a 5-min period), thus
allowing a better estimation of insulin kinetics. In this case the model was
used in two different ways: at first, analyzing all the available plasma samples,
then, neglecting the insulin infusion and just considering the former part of
the test. Interestingly, the model provided a good correlation among the HE
parameters in these two different occasions.
In summary, we have developed a model of insulin kinetics which contains
a new physiological description of HE. This model allows a good prediction
of the available data during meals and OGTT in all the spectrum of glucose
tolerance (healthy, intolerant and T2DM), also providing a powerful new
index of HE sensitivity to glucose.
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Italiano
La regolazione del metabolismo del glucosio, in soggetti sani, si basa su un
complesso sistema di controllo, che mira a mantenerne la concentrazione pla-
smatica in un range limitato (70÷180 mg/dl). L'insulina, un ormone secreto
dalle beta-cellule pancreatiche, ha un ruolo fondamentale nell'omeostasi del
glucosio, riducendone la produzione epatica, e stimolandone l'utilizzazione
da parte degli organi insulino-dipendenti. L'incapacità da parte delle beta-
cellule di secernere adeguatamente l'insulina può creare problemi metabolici,
che possono anche provocare uno stato di intolleranza al glucosio, o addi-
rittura il diabete mellito. Esistono due diversi tipi di diabete: il diabete di
tipo 1 (T1DM), caratterizzato da una totale impossibilità di secernere in-
sulina da parte delle beta-cellule pancreatiche, e il tipo 2 (T2DM), in cui,
a causa dell'insulino-resistenza, i tessuti non riescono a utilizzare adeguata-
mente il glucosio, e la secrezione insulinica è insufficiente per compensare
questo difetto. Data la crescente diffusione del diabete, comprendere tutti i
meccanismi coinvolti nel sistema di regolazione del glucosio è molto impor-
tante.
Il fegato è un organo fondamentale nella regolazione del glucosio, poichè è
anche responsabile dei livelli di insulina plasmatica, estraendone circa il 50%
dalla circolazione portale, ad ogni passaggio attraverso di esso. La quanti-
ficazione dell'estrazione insulinica epatica (HE), sia in condizioni basali che
in condizioni dinamiche (come per esempio dopo un carico orale di glucosio),
è quindi fondamentale per descrivere il metabolismo del glucosio. Dato che
una misura diretta di HE è molto invasiva, richiedendo l'inserzione di cate-
teri nella vena porta e epatica, si preferisce utilizzare metodi indiretti, basati
sui modelli matematici. Tali modelli richiedono misure delle concentrazioni
plasmatiche, e la conoscenza della cinetica del C-peptide, della secrezione e
della degradazione dell'insulina. È infatti noto che insulina e C-peptide sono
secreti in maniera equimolare dalle beta-cellule pancreatiche, ma soltanto
l'insulina viene poi estratta dal fegato.
Il primo modello disponibile in letteratura per descrivere HE è stato svi-
luppato da Toffolo et al., e descrive HE durante un insulin-modified intraven-
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ous glucose tolerance test (IM-IVGTT); questo modello fornisce una stima
della secrezione insulinica (ISR) e della velocità di comparsa dell'insulina nel
plasma (IDR), rispettivamente dalle concentrazioni di C-peptide e insulina.
HE viene quindi calcolata da questi due flussi. Più recentemente, Cam-
pioni et al. hanno proposto un modello di stima di HE durante pasto. In
questo caso HE è descritta come una funzione lineare a tratti, con un numero
prefissato di punti, che sono i parametri stimati dal modello. La limitazione
principale di questo approccio è che, benchè il profilo di HE venga ricostruito,
non è fornita una relazione meccanicistica tra le variabili coinvolte, e quindi
i parametri del modello non hanno un'immediata interpretazione fisiologica.
Inoltre, la struttura del modello rende l'identificazione parametrica sensibile
al rumore, poichè il profilo di HE può essere soggetto a rapide variazioni a
seguito delle fluttuazioni della concentrazione di insulina periferica.
Lo scopo di questo lavoro è quindi di superare gli svantaggi della descri-
zione di HE attualmente disponibile, proponendo un nuovo modello fisiologico
della cinetica e estrazione dell'insulina. Il modello migliore viene selezionato
tra sette nuovi modelli, che includono un numero di compartimenti crescente,
e diverse descrizioni fisiologiche di HE, ciascuna contenente l'influenza di uno
o più controlli, come le concentrazioni plasmatiche di glucosio e insulina. In-
fatti, durante un test orale è possibile osservare che, mentre le concentrazioni
di glucosio e insulina salgono, il profilo temporale di HE decresce. Questi
modelli sono stati testati in 204 soggetti sani studiati con un pasto misto e
campionato frequentemente (21 campioni). Il modello migliore è quindi stato
selezionato in base a criteri standard (abilità di predizione dei dati, precisione
delle stime parametriche, parsimonia). Tale modello risulta comprendere una
descrizione della cinetica dell'insulina a tre compartimenti, dove HE è fun-
zione della concentrazione di glucosio. Una delle peculiarietà del modello
è la possibilità di ottenere un indice di sensibilità di HE al glucosio (SHEG ),
oltre agli usuali indici basale (HEb) e totale (HEtot) di HE, già presenti in
letteratura. Inoltre, il nuovo modello fornisce buone performance anche in
dati raccolti con un campionamento standard, quindi meno frequente (11
campioni).
x Abstract
Il modello selezionato è stato quindi utilizzato in altri tre diversi database,
costituiti da soggetti con vari gradi di tolleranza al glucosio, studiati durante
un pasto misto standard, o un test orale di tolleranza al glucosio (OGTT). Il
primo data set impiegato è composto da 62 soggetti prediabetici (ovvero sani,
intolleranti al glucosio, e soggetti con ridotta glicemia a digiuno), sottoposti
sia a un pasto misto con triplo tracciante, sia a un OGTT. Il modello si è
dimostrato in grado di descrivere i dati adeguatamente durante entrambi i
test, e gli indici di HE mostrano una correlazione con il grado di disfunzione
nel metabolismo del glucosio. Il secondo data set consiste di 11 soggetti sani
e 14 T2DM, di simile età, peso e indice di massa corporea (BMI), sottoposti
a pasto misto con triplo tracciante. Anche in questo caso il nuovo modello
è in grado di predire i dati, e gli indici di HE (HEb, HEtot, SHEG ) risultano
significativamente diversi nei due gruppi. L'ultimo database è costituito da 14
soggetti T2DM, trattati sia con vildagliptin che con placebo prima del pasto;
inoltre in t = 300 min, sono state somministrate 0.02 unità/kg di insulina
per via endovenosa (in un periodo di 5 minuti), permettendo quindi una
migliore stima della cinetica dell'insulina. In questo caso il modello è stato
usato in due modi differenti: prima analizzando tutti i campioni plasmatici
a disposizione, quindi, successivamente, trascurando l'infusione di insulina, e
considerando solo la parte iniziale del test. Un risultato interessante riguarda
il fatto che il modello fornisce una buona correlazione tra i parametri di HE,
calcolati nelle due diverse identificazioni.
Quindi, riassumendo, è stato sviluppato un modello della cinetica dell'insulina,
contenente una nuova descrizione fisiologica di HE. Questo modello permette
una buona predizione dei dati disponibili durante pasto e OGTT, in tutto lo
spettro di tolleranza al glucosio (soggetti sani, intolleranti e T2DM), fornendo
inoltre un nuovo indice di sensibilità di HE al glucosio.
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ADA American Diabetes Association
BMI Body Mass Index
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CV Coefficient of Variation
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IDE Insulin Degrading Enzyme
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Introduction
1.1 Background
The regulation of glucose metabolism is based on a complex control sys-
tem that, in healthy conditions, aims to maintain plasma glucose concen-
tration within a narrow range (from 70 to 180 mg/dl), over the whole day.
Therefore, the correct operation of this control is fundamental, in order to
avoid plasma glucose levels falling below 70 mg/dl, or rising over 180 mg/dl,
causing hypoglycemia or hyperglycemia, respectively [18]. Both these abnor-
mal states have adverse consequences. Hypoglycemia may cause impaired
brain function, due to an inadequate glucose provision, which can result in
dysphoria, but also seizures, unconsciousness, and death. Hyperglycemia is
problematic as well, since it can be associated with chronic states, leading
to cardiac, neuronal, renal and retinal diseases [18, 23]. Therefore, a com-
plete understanding of all the mechanisms involved in the glucose metabolism
regulation is essential.
Plasma glucose concentration results from the balance of the rate of gluc-
ose entering the circulation (glucose rate of appearance, Ra), and the rate of
its removal from the circulation (glucose rate of disappearance, Rd). Blood
glucose is mainly provided by three different sources: intestinal absorption
during the fed state, glycogenolysis, and gluconeogenesis. Glycogenolysis and
gluconeogenesis are hepatic processes, stimulating, respectively, the break-
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down of glycogen as a storage form of glucose, and the formation of glucose
from lactate and aminoacids during the fasting state; both processes are
partly controlled by glucagon, a hormone produced by the pancreatic alpha-
cells.
In the first 8÷12 hours of fasting, glycogenolysis is the primary mechanism
responsible for glucose availability. This process is stimulated by glucagon,
thus promoting glucose appearance in the circulation. Over longer periods
of fasting, glucose coming from gluconeogenesis is released from the liver [2].
Many hormones are involved in the glucose regulatory system: insulin,
glucagon, amylin, Glucagon-like Peptide 1 (GLP-1), glucose-dependent in-
sulinotropic peptide (GIP), epinephrine, cortisol, and growth hormone. Among
them, insulin and amylin are secreted by the pancreatinc beta-cells, glucagon
by the pancreatic alpha-cells, GLP-1 and GIP by the intestinal L-cells [2].
Insulin is considered the main hormone responsible for glucose homeostasis,
since it provides a hypoglycemic effect, by decreasing liver and kidney glucose
production, while promoting its utilization by the insulin-dependent organs
(skeletal muscles and adipose tissues), and suppressing the post-prandial glu-
cagon secretion. Normally, it is secreted in response to increased blood gluc-
ose and aminoacids following ingestion of a meal, while it is not secreted
when glucose levels are ≤ 60 mg/dl [2].
Glucagon effect is opposite that of insulin, since it is responsible for raising
plasma glucose concentrations, when hypoglycemia occurs. It plays a major
role in sustaining plasma glucose during fasting conditions by stimulating
hepatic glucose production and gluconeogenesis. On the other hand, imme-
diately after a meal, an endogenous source of glucose is not needed, and thus
glucagon secretion is suppressed.
Acting together, glucagon and insulin make up a feedback system that reg-
ulates blood glucose levels [2].
The inability of this control system to adequately work creates meta-
bolic disorders which can result in different degrees of glucose intolerance or
diabetes mellitus. Diabetes is a social pathology, characterized by chronic
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hyperglycemia, in which insulin secretion and action are not sufficient to
maintain blood glucose levels in the normal range. As a result, postprandial
glucose concentrations rise due to lack of insulin-stimulated glucose disap-
pearance, poorly regulated hepatic glucose production, and increased or ab-
normal gastric emptying following a meal. There are two different kinds of
diabetes: type 1 diabetes (T1DM), and type 2 diabetes (T2DM).
T1DM, aicting 5÷10% of all the diabetic population, also known as "insulin-
dependent", is characterized by the inability of pancreatic beta-cells to secrete
insulin, as a consequence of their immune-mediated destruction. This kind
of pathology mostly arises in children and adolescents, and is thus called
juvanile diabetes. The absolute lack of insulin causes hyperglycemia because
of an impaired hepatic glucose production regulation, and an interruption of
glucose utilization; therefore exogenous insulin administration is necessary,
in order to compensate for the lack of a correct glucose control.
T2DM, aicting 90÷95% of all the diabetic population, is also known as
"insulin-independent"; tissues are unable to appropriately utilize glucose
because of insulin resistance, and insulin secretion cannot compensate for
this. Being insulin secretion impaired, even if not completely absent, it is
always possible to find circulating insulin; nevertheless, T2DM causes hyper-
glycemia, too. This kind of pathology especially arises in adult and elderly
people, and it is often associated with obesity. Typical therapies for T2DM
concern an improvement of lifestyle, consisting of a regular diet and phys-
ical exercise; sometimes also drugs are necessary (metformin, sulfonylureas,
meglitinides, thiazolidinediones and many others), as well as an insulin treat-
ment.
Diabetes mellitus is characterized by highly invalidating complications, that,
in the long term, can cause serious pathologies, as such as cardiovascular
diseases, retinopathy, kidney's disorders, impotence, neuropathy and neph-
ropathy. The International Diabetes Federation (IDF) estimates that 8.3% of
adults (382 million people) have diabetes, and the number of affected people
is set to rise beyond 592 million in less than 25 years [33], that is why dia-
betes is considered a social pathology.
T2DM is often preceded by prediabetes, characterized by an impaired gluc-
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ose control which can make plasma glucose level rise, even if the consequent
hyperglycemia is not enough to be considered diabetes. The prediabetes dia-
gnosis is usually performed by two different tests: the fasting plasma glucose
test (FPG), and the oral glucose tolerance test (OGTT). The FPG, accord-
ing to the ADA criteria [18], allows to distinguish normal fasting glucose
(NFG, blood glucose level ≤ 5.2 mmol/l) and impaired fasting glucose sub-
jects (IFG, blood glucose level between 5.2 mmol/l and 7 mmol/l). IFG is
thus considered an early form of diabetes, and its severity can be classified by
using the OGTT, understanding whether people are affected by normal gluc-
ose tolerance (NGT), impaired glucose tolerance (IGT), or diabetes (DM).
Subjects with IFG are at 20÷30% risk of progressing to T2DM in the follow-
ing 5÷10 years; this risk is even higher if they are also affected by IGT.
Given the increasing prevalence of all the spectrum of glucose intolerance
pathologies, a complete understanding of all the mechanisms involved in the
glucose regulation system is fundamental.
The liver plays an essential role in glucose metabolism since, beside pro-
ducing glucose, it is also the main site of insulin extraction. In fact, the
amount of insulin reaching the systemic circulation is dependent not only
on beta-cell secretion, but also on hepatic insulin extraction, since approx-
imately 50% of the endogenous secreted insulin is removed from the portal
circulation by the liver during its first-pass transit [12], even if this percent-
age varies under different conditions.
Insulin degradation has been overlooked for a long time, but it is really im-
portant, because it contributes to the cellular control on insulin, and it is
thus related to insulin action. It has been demonstrated that insulin has a
short half-life (4÷6 min), so it needs to be promptly removed, according to
the blood glucose variations [21].
Hepatic insulin uptake is not a static process, because it is influenced by
physiological and pathological factors, involving several different systems and
controls [21]. It is a receptor-mediated mechanism, in which high insulin con-
centrations stimulate a decrease of fractional uptake, even if the total uptake
is increased [22, 35]. Moreover, high portal insulin levels cause an impaired
clearance, due to receptor down-regulation.
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However, it is important to remark that insulin removal from plasma circula-
tion does not implicate its sudden destruction, since a significant portion of
it can then be released from the cells, and thus reenter the blood circulation.
For example, the muscles can capture, and then release insulin back into the
circulation [22].
A further important aspect concerning the alterations of insulin clearance, is
nutrient intake. In general, it has been demonstrated that the oral glucose in-
gestion, differently from the portal infusion, can increase the hepatic insulin
uptake process, probably because of the presence of gut signals. However
glucose, by increasing insulin secretion, may also decrease the hepatic insulin
extraction [21]. Also free fatty acids (FFA) may interfere with hepatic insulin
degradation, to such an extent that they may be involved in the pathogenesis
of T2DM, by inhibiting insulin binding, degradation and action in the liver
[49].
Hepatic insulin clearance has been demonstrated to decrease in obese and
diabetes patients. Furthermore, liver disease may also cause a decrease in
hepatic insulin degradation, which could consequently be associated with re-
duced insulin sensitivity, thus supporting the strong connection between it
and the whole insulin action [49].
For all these reasons, hepatic insulin extraction, by removing and inactivating
insulin, has an important role in the glucose regulation system.
1.2 Aim
The general aim of this thesis is to develop a new oral model for the estim-
ation of hepatic insulin extraction, which is able to describe insulin secretion
and kinetics in all the spectrum of glucose tolerance (healthy, prediabetic,
and T2DM subjects).
In particular, the specific tasks of this work are:
• To choose an optimal model of hepatic insulin extraction in healthy
subjects that underwent a meal.
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• To use the model in prediabetic subjects, as well as in T2DM subjects,
also testing its performance during an OGTT.
• To compare the results obtained by considering different pathology
levels.
1.3 Outline
This thesis is organized as follows:
• Chapter 2 provides a basic overview on the physiological processes in-
volved into the hepatic insulin uptake and degradation, at a cellular
level.
• Chapter 3 summarizes the most recent mathematical models proposed
in the literature, used to quantify hepatic insulin extraction.
• Chapter 4 describes all the databases involved in this thesis, as well as
all the experimental protocols.
• Chapter 5 presents the new insulin kinetics and hepatic insulin extrac-
tion models, proposed in this work.
• Chapter 6 reports all the model selection process, in healthy subjects,
during a meal test.
• Chapter 7 contains the results obtained by using the selected models
in prediabic and T2DM subjects, during meal and OGTT.
The results of this thesis, as well as all the possible future developments and
open questions, are discussed in the Conclusions.
2
Hepatic insulin uptake and degradation
2.1 Introduction
As mentioned in chapter 1, the liver, and thus the hepatocytes, account
for the majority of the insulin uptake and degradation, even if this process is
also peculiar to all insulin-sensitive tissues; thus insulin is endocytosed and
degraded in most cell types (for example, adipocytes and fibroblasts). In this
chapter, a brief overview of the cellular mechanisms of insulin uptake and
degradation is provided.
2.2 Insulin uptake and degradation
The insulin degradation process is very complex and has multiple com-
ponents, thus the topic is still very controversial. The process is sequen-
tial, involving an initial reductive cleavage of the insulin molecule, with sub-
sequent proteolysis of separate chains [21].
Cellular insulin internalization can be operated by pinocytosis, especially
when its concentration is high [21], but the main mechanism of cellular up-
take is a receptor-mediated system.
The first step is the insulin binding by its receptors (see Fig. 2.1), which
creates an insulin reserve that can either return to the circulation, or be
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transported to an intracellular site [29]. Multiple pathways are possible: in-
sulin can either be degraded in endocytotic vesicles [3, 48], or, alternatively,
it can remain intact, and be released from the cells by diacytosis or retroen-
docytosis to other subcellular sites.
The main locations of internalized insulin are the cytosol, nucleus, and Golgi
[21], in which insulin can be directly degraded, or delivered to lysosomes for
the ultimate degradation step [45]. Also partially degraded insulin can return
to the circulation [38], retaining receptor binding and biological activity [58].
The receptor-bound insulin is usually internalized into the cellular en-
dosomes [28], by an energy-requiring adsorbitive endocytosis, and then the
degradation process starts. After their formation, the endosomes quickly
acidify, and insulin is thus dissociated from the receptor within the ves-
cicle. Insulin degradation begins just before the acidification mechanism
[28], thanks to the specific insulin degrading enzyme (IDE). The receptor-
bound insulin is a substrate for IDE [20], that is present in endosomes, but
also in cytosol, plasma membranes, and peroxisomes [21]; it is responsible for
starting the cellular insulin process, and degrading of a significant portion of
it on the cell membrane.
There is evidence that suggests that IDE overexpression regulates cellular
insulin degradation by increasing the process [36].
Insulin-IDE interactions are very important since many studies support the
hypothesis that they could modulate fat and protein metabolism [21].
The quantification of endosomes degradation is variable, depending on insulin
concentration, duration of exposure, and many other factors [43]. Typically,
50% of insulin amount is degraded, and the remaining portion is delivered to
other subcellular compartments, as such as cytosol, nucleus and lysosomes
[30], using pathways which involve IDE action [1].
While the first degradation occurring immediately after cells exposure to in-
sulin takes place in endosomes, the fraction of insulin that remains intact, or
just partially degraded, is then carried to the lysosomes, where it is finally
metabolized [21].
After the degradation products are released into the medium by exocytosis,
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the receptor is recycled in a vescicle to the plasma membrane, so that, nor-
mally, no accelerated net consumption of the receptor takes place [46].
It is important to remark that some studies have noticed a "downregula-
tion" of the degradation process, operated by insulin: the hyperinsulinemic
state induces a loss of receptors, or makes them unavailable for binding and
endocytosis, i.e. insulin induces an acceleration of the rate of receptors de-
gradation in some tissues, without altering their rate of synthesis, leading to
a reduced number of receptors.
Insulin 
Insulin receptor 
a 
b 
c1 
c2 
c3 
d 
Figure 2.1: Pathways for the internalization and processing of insulin. After
insulin binds to its plasma membrane receptor, it is internalized in a endocytic
vescile (a). This vesicle then undergoes acidification, which causes the insulin to
dissociate from its receptor (b). Insulin is then degraded in endosomes (c1), or
traslocated to cytosol and degraded there (c2), or delivered to other subcellular
compartments, as such as peroxisomes (c3). The receptor is recycled in a vescicle
to the plasma membrane (d). Adapted from [37].

3
State of the art models of hepatic insulin
extraction
3.1 Introduction
In this Chapter two models, previously proposed for assessing hepatic
insulin extraction (HE), are described: an IM-IVGTT and an oral model.
Afterwords, their limitations are highlighted.
As previously mentioned, the liver plays a fundamental role in glucose
metabolism since, besides producing glucose, it is responsible of regulating
insulin levels by extracting a significant fraction of the secreted insulin. Pre-
vious studies have demonstrated that the liver removes about 50% of insulin
appearing in the portal circulation, at every passage through it. Therefore,
the assessment of hepatic insulin extraction, in the basal state as well as
in dynamic situations, is a crucial point for completely understanding the
glucose metabolism [15].
The HE process appears to be dynamic and is affected by, amongst other
parameters, the amplitude of portal insulin pulses [39], circulating free fatty
acids [57], and hyperglycemia per se [21]. Unfortunately, a direct measure-
ment of HE is very invasive, requiring the insertion of catheters into the
portal and hepatic veins, respectively. For these reasons, the estimation of
HE using mathematical models, despite being an indirect method (since usu-
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ally models employ plasma concentration measurements), is more applicable
to well-powered studies in humans [26]. Such models are based on the evid-
ence that C-peptide and insulin are secreted into the portal vein in equimolar
concentrations by the beta-cells and the fact that the liver extracts insulin,
but not C-peptide. Thus, from plasma C-peptide and insulin concentrations
it is possible to make inferences on the process of HE.
Several models estimating HE after an oral or intravenous glucose per-
turbation are available in the literature [14, 24, 53, 56], but they suffer from
two main limitations. First of all, the simultaneous estimation of secretion
and kinetics negatively affects the assessment of the secretion, because of
possible unexpected parameter compensations [52]. Secondly, the fact that
HE is sometimes considered a constant variable is not realistic, since there is
evidence of its variability with time [53].
3.2 Models
3.2.1 The IM-IVGTT model
Toffolo et al. [50] proposed a model for the assessment of HE during an
IM-IVGTT.
This method employs the minimal model of C-peptide secretion and kin-
etics [24], coupled with a model of insulin kinetics [50]. This last is well
identifiable during an IM-IVGTT thanks to the square-wave insulin infusion
administrated 20 min after the glucose bolus [51].
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The C-peptide minimal model. C-peptide kinetics is described by a two
compartment model [24] (as shown in Fig. 3.1):
˙CP 1(t) = −(k01 + k21) · CP1(t) + k12 · CP2(t) + isr(t) CP1(0) = C1b
(3.1)
˙CP 2(t) = −k12 · CP2(t) + k21 · CP1(t) CP2(0) = C1b · k21
k12
(3.2)
CP (t) = CP1(t) (3.3)
where CP1 and CP2 (pmol/l) are C-peptide concentrations in the accessible
and in the peripheral compartment, respectively, CP (pmol/l) is the meas-
ured C-peptide concentration, C1b (pmol/l) the end test C-peptide concen-
tration, k01, k21, k12 (min−1) rate transfer parameters, and isr (pmol/l/min)
is the secretion rate, normalized by the volume of distribution of compart-
ment 1, Vc (l).
isr is assumed to be proportional to the amount of insulin contained in the
Delay 
Glucose 
Glucose Rate 
of Change 
Releasable 
Insulin 
CP1 CP2 
k12 
k21 
k01 
ISR 
Y 
X0 
2nd Phase 
1st Phase 
INSULIN SECRETION 
β-cell 
C-PEPTIDE KINETICS 
Figure 3.1: Minimal model of C-peptide secretion and kinetics during an IM-
IVGTT. CP1 and CP2 (pmol/l), plasma C-peptide concentrations in the accessible
and peripheral compartments; k01, k12, k21 (min
−1), rate transfer parameters; ISR
(pmol/min), insulin secretion rate; Y (pmol/l/min), new insulin provision; X0
(pmol/l), first phase secreted insulin.
beta-cells, X (pmol/l), which is related to the provision of new insulin in the
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beta-cells, Y (pmol/l/min), with a first order differential equation:
isr(t) = m ·X(t) + k01 · C1b (3.4)
X˙(t) = −m ·X(t) + Y (t) X(0) = X0 (3.5)
X0 accounts for the first-phase secretion, while the second-phase derives from
Y and is controlled by glucose:
Y˙ (t) = −α · {Y (t)− β · [G(t)− h]} Y (0) = 0 (3.6)
Evidently from Eq. (3.6), when the glucose level is high, Y and isr tend with
a rate constant 1/α (min) towards a steady state which is linearly related to
glucose concentration G above the threshold level h, via the parameter β.
The total insulin secretion rate, ISR (pmol/min), is reconstructed as follows:
ISR(t) = isr(t) · Vc = [k01 · C1b +m ·X(t)] · Vc (3.7)
This model allows the calculation of indexes representing basal secretion, as
well as the first and second-phase beta-cell responsivity to glucose. The basal
secretion index Φb (10−9 min−1) is defined as:
Φb = isrb/Gb = k01 · C1b/Gb (3.8)
where Gb is the end-test glucose concentration.
Φ1 (10−9) is the first-phase glucose responsivity index, calculated as:
Φ1 = X0/∆G (3.9)
where ∆G (mmol/l) is maximum glucose increment above basal.
The second-phase glucose responsivity index, Φ2 (10−9 min−1), which de-
scribes the stimulation of insulin provision, operated by glucose, is calculated
as:
Φ2 = β (3.10)
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The insulin minimal model. Insulin kinetics is well described by a single-
compartment model [50] (see Fig. 3.2):
I˙(t) = −n · I(t) + idr(t) + U(t)/VI I(0) = Ib (3.11)
where Ib (pmol/l) and I (pmol/l) are, respectively, the end-test and the
measured insulin concentration, n (min−1) is the rate constant of insulin
disappearance, idr (pmol/l/min) is the insulin delivery rate, normalized by
insulin volume of distribution VI (l), and U (pmol/min) is the exogenous
insulin infusion, usually administrated in the 20÷25 min interval. According
to [50], idr is here described similarly to isr:
idr(t) = mIDR ·XIDR(t) + n · Ib (3.12)
X˙IDR(t) = −mIDR ·XIDR(t) + Y IDR(t) XIDR(0) = XIDR0
(3.13)
Y˙ IDR(t) = −αIDR · {Y IDR(t)− βIDR · [G(t)− h]} Y IDR(0) = 0 (3.14)
where the apex "IDR" indicates that parameters refer to insulin delivery
rate, i.e. they combine both insulin secretion rate and hepatic extraction.
IDR (pmol/min) can be obtained as:
IDR(t) = idr(t) · VI = [n · Ib +mIDR ·XIDR] · VI (3.15)
Insulin delivery rate indexes of basal, first- and second-phase responsivity
to glucose were calculated, similarly to Eq. (3.8), (3.9), (3.10):
ΦIDRb = idrb/Gb = n · Ib/Gb (3.16)
ΦIDR1 = X
IDR
0 /∆G (3.17)
ΦIDR2 = β
IDR (3.18)
where Gb is the end-test glucose concentration.
Using ISR and IDR time courses it is possible to reconstruct the HE pro-
file, as well as indexes of basal (HEb) and a total (HEtot) hepatic insulin
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extraction:
HE(t) =
ISR(t)− IDR(t)
ISR(t)
= 1− IDR(t)
ISR(t)
(3.19)
HEb =
isrb · Vc − idrb · VI
isrb · Vc = 1−
ΦIDRb · VI
Φb · Vc (3.20)
HEtot =
∫ T
0
ISR(t)dt− ∫ T
0
IDR(t)dt∫ T
0
ISR(t)dt
= 1− (Φ
IDR
b + Φ
IDR
1 · A1 + ΦIDR2 · A2) · VI
(Φb + Φ1 · A1 + Φ2 · A2) · Vc
(3.21)
A1 =
∆G
T ·Gb (3.22)
A2 =
∫ T
0
[G(t)− h]dt
T ·Gb (3.23)
where T is the duration of the experiment.
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Figure 3.2: Minimal model of insulin secretion and kinetics during an IM-IVGTT.
I (pmol/l), plasma insulin concentration; n (min−1), rate constant of insulin disap-
pearance; U (pmol/min), exogenous insulin infusion; IDR (pmol/min), posthepatic
insulin delivery rate; Yidr (pmol/l/min), comparable to new insulin provision; Xidr0
(pmol/l), first-phase secreted insulin.
It is of note that in this model the C-peptide kinetic parameters (Vc,
k12, k01, and k21) are fixed in each subject, according to the anthropometric
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characteristics (BSA and BMI), as proposed in [55], in order to avoid pos-
sible compensations among secretion and kinetic parameters. For insulin, the
estimation of both kinetics and IDR was made possible thanks to the pecu-
liarity of the IM-IVGTT protocol, in which an insulin concentration decay
can be measured after the short insulin infusion.
3.2.2 The oral model
In order to extend the approach used by Toffolo et al. in [50] to assess HE
during a more physiological oral glucose test, Campioni et al. [11] proposed a
single-compartment insulin minimal model to assess IDR, here namedModel
of Data, due to the piecewise linear description of HE [see Eq. (3.34) later].
For C-peptide kinetics and secretion, previous models available in literature
were used [10, 24].
The C-peptide minimal model. C-peptide kinetics is described by the
same two-compartment model shown in Eq. (3.1)-(3.2) [24].
The pancreatic secretion ISR (pmol/min) is described as the sum of three
different components [10] (see Fig. 3.3): basal ISRb, static ISRs, propor-
tional to glucose concentration, and dynamic ISRd, proportional to glucose
rate of increase:
ISR(t) = ISRb + ISRs(t) + ISRd(t) (3.24)
ISRb can be obtained from steady state constraint of (3.24):
ISRb = CPb · k01 · Vc (3.25)
ISRs represents the provision of releasable insulin controlled by glucose con-
centration G (mmol/l) in a linear dynamic way: if plasma glucose shows a
step increase above a threshold level h (mmol/l), the provision tends with
a rate constant α (min−1), and thus with a delay T = 1/α (min), toward a
steady-state value that is linearly dependent to the glucose step through a
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parameter β (10−9 min−1):
˙ISRs(t) = −α · [ISRs(t)− Vc · β·(G(t)− h)] ISRs(0) = 0 (3.26)
ISRd is the secretion of insulin from the promptly releasable pool, and it is
proportional to the rate of increase of glucose G˙ (mmol/l/min) through the
parameter Kd (10−9):
ISRd =
Vc ·Kd · G˙(t) if G˙(t) ≥ 00 if G˙(t) < 0 (3.27)
Delay 
Glucose 
Glucose Rate 
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CP1 CP2 
k12 
k21 
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ISR Static 
Dynamic 
INSULIN SECRETION 
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Figure 3.3: Minimal model of C-peptide secretion and kinetics during an oral
test. CP1 and CP2 (pmol/l), plasma C-peptide concentrations in the accessible
and peripheral compartments; k01, k12, k21 (min
−1), rate transfer parameters; ISR
(pmol/min), insulin secretion rate.
The model allows the estimation of the basal, i.e. Φb (10−9 min−1), static,
i.e. Φs (10−9 min−1), and dynamic, i.e. Φd (10−9), indexes of sensitivity to
glucose; moreover, a total index Φtot (10−9 min−1) accounting for both the
static and dynamic component can be obtained.
Φb, similarly to Eq. (3.8), is defined as:
Φb = isrb/Gb = k01 · CPb/Gb (3.28)
3.2 Models 19
where Gb (mmol/l) and CPb (pmol/l) are, respectively, basal glucose and
C-peptide concentrations.
Φs measures effect of glucose on beta-cell secretion and is thus defined as the
ratio between ISR and glucose concentration above basal at steady state; it
can be easily calculated as:
Φs = β (3.29)
Φd measures the effect of glucose rate of increase on the secretion of stored
insulin; it is defined as the amount of insulin (per unit of C-peptide volume
of distribution) released in response to the maximum glucose concentration
achieved during the experiment, normalized by the glucose increase; it is ob-
tained as:
Φd = Kd (3.30)
Φtot combines Φs and Φd; it is defined as the average increase above basal of
pancreatic secretion over the average glucose stimulus above the threshold
level h, and can thus be calculated as:
Φtot = Φs +
Φd ·∆G∫∞
0
[G(t)− h]dt (3.31)
where ∆G (mmol/l) is the maximum glucose increment above basal.
The insulin minimal model. Similarly to [50], a linear single-compartment
model which describes insulin kinetics [11] is adopted (see Fig. 3.4):
I˙(t) = −n · I(t) + idr(t) I(0) = Ib (3.32)
where Ib (pmol/l) and I (pmol/l) are, respectively, basal and measured in-
sulin concentration, n (min−1) is the rate constant of insulin clearance, idr
(pmol/l/min) is the insulin delivery rate, normalized by insulin volume of
distribution VI (l).
IDR (pmol/min) is the post-hepatic insulin delivery rate, i.e. the fraction
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Figure 3.4: Minimal model of insulin secretion and kinetics during an oral test. I
(pmol/l), plasma insulin concentration; n (min−1), rate constant of insulin disap-
pearance; ISR (pmol/min), insulin secretion rate; IDR (pmol/min), post-hepatic
insulin delivery rate; HE (dimensionless), hepatic insulin extraction.
(1−HE) of secreted insulin (ISR) which is not extracted by the liver:
IDR(t) = ISR(t) · [1−HE(t)] (3.33)
Campioni et al. [11], proposed a parametric description of HE, so that recon-
struction of the HE profile is treated as a parameter estimation problem. The
most general expression is a piecewise linear function with a given number
of breakpoints:
HE(t) =
HEi−1 +
HEi−HEi−1
(ti−ti−1) · (t− ti) ti−1 < t < ti
HE0 = HEb
(3.34)
where HEb is basal hepatic insulin extraction, and HEi are the paramet-
ers to be estimated, representing the values of HE(t) at given time points
i = 1, 2, ..., 6. HE(t) is supposed to vary more rapidly in the first part of
the test, thus the intervals [ti−1, ti] are shorter at the beginning and longer
toward the end (ti = 0, 20, 40, 90, 150, 210 and 420 min in [11]).
A total index of HE, HEtot, is derived using the first part of Eq. (3.21):
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HEtot =
∫ T
0
ISR(t)dt− ∫ T
0
IDR(t)dt∫ T
0
ISR(t)dt
(3.35)
while the basal index HEb, appearing in Eq. (3.34), is obtained from basal
ISR and IDR, i.e. from basal insulin and C-peptide concentrations, similarly
to Eq. (3.20) as:
HEb =
ISRb − IDRb
ISRb
= 1− Ib · n · VI
CPb · Vc · k01 (3.36)
As mentioned in par. 3.2.1, the C-peptide kinetic parameters are fixed
according to [55], while for insulin kinetic parameters, linear regression mod-
els linking n, VI and insulin clearance CLI = n·VI (l/min) to anthropometric
characteristics (BSA and age) were developed [11] (see later, par. 5.5.2). In
so doing, it was made possible to estimate insulin kinetic parameters even in
databases for which IM-IVGTT data are not available [11].
3.3 Limitations
The model proposed by Toffolo et al. for estimating HE during an IM-
IVGTT [50], surely overcomes the problem of undesired parameter estimation
compensation due to the simultaneous description of both secretion and kin-
etics from the same experiment. In fact, as mentioned above, the C-peptide
kinetics parameters are fixed to standard values [24], while insulin kinetics
and IDR parameters are estimated thanks to the typical IM-IVGTT insulin
infusion. However, this model proposes a similar functional description for
ISR and IDR, which are both made up of two components: the first phase
proportional to the rapid rise in glucose concentrations, and the second phase
proportional to the delayed rise in plasma glucose concentration.
The extension of the model proposed by Toffolo et al. to an oral glucose
test is not straightforward since the same IDR description cannot be used,
and a priori knowledge of insulin kinetics is necessary to assess this flux. For
these reasons, Campioni et al. [11] had to initially develop a new model of
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IDR, together with a new method for determining standard parameters of
insulin clearance, and then, consequently, a new description of HE as a piece-
wise linear function with a fixed number of breakpoints. At variance with
[53], where HE was assumed to be constant during an oral test, Campioni et
al. considered it as a time varying profile, according to evidence obtained by
measurements using hepatic vein catheterization, which also suggested that
HE is strongly related to blood flow [53].
However, the main limitation of this method arises from how HE is described:
a piecewise linear function with a given number of breakpoints allows recon-
struction of a profile, but does not investigate the mechanistic relationship
between the involved variables, and does not provide physiologically mean-
ingful parameters. Moreover, this expression makes the model vulnerable to
noise, since the HE profile may rapidly vary to fit fluctuations in peripheral
insulin concentrations.
4
Database and Protocols
4.1 Introduction
In this Chapter the databases and protocols, used at first to assess and
then to apply the new HE oral model, are described. For the development
and selection of the model, a database made up of 204 healthy subjects who
underwent a standard mixed meal is used (database 1 ). Then, the abilities
of this model are tested across the spectrum of glucose tolerance, employ-
ing data of prediabetic subjects (both impaired fasting glucose and impaired
glucose tolerant, composing database 2 ) collected during OGTT and mixed
meal, and type 2 diabetic subjects (database 3 and 4 ).
4.2 Database 1: healthy subjects
Subjects. The study cohort [6] is made up of 204 healthy subjects [86
elderly men (EM), 59 elderly women (EW), 31 young men (YM), and 28
young women (YW); age 55.5±1.5 yr (means±SE), BMI 26.6±0.2 kg/m2,
BSA 1.90±0.01 m2], who were in good health and not involved in regular
vigorous physical activity.
All subjects consumed a weight maintenance diet (55% carbohydrate, 15%
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protein, and 30% fat) for 3 days preceding the study; subsequently, they were
admitted to the Mayo Clinic CRU at 1600 on the afternoon before study and
had a standard 10-kcal/kg meal (55% carbohydrate, 15% protein, and 30%
fat), which was consumed between 1700 and 1730. No additional food was
eaten until the next morning.
Mixed meal protocol. At 0600 on the morning of the study, an 18-gauge
cannula was put in a retrograde fashion into a dorsal hand vein. The hand
was then placed in a heated plexiglas box (∼ 55◦C) to obtain arterialized
venous blood samples. A further 18-gauge cannula was inserted in the op-
posite forearm for tracers infusion (not used in this work). At 0900 (0 time),
a mixed meal (10 kcal/kg, 45% carbohydrate, 15% protein, and 40% fat)
made up of scrambled eggs, Canadian bacon, [1-13C]glucose Jell-O (contain-
ing 1.2 g/kg body wt dextrose) was consumed within 15 min, according to
[5]. Blood was frequently sampled (FS-MTT ) [5] from the arterialized venous
site at t = -120, -30, -20, -10, 0, 5, 10, 15, 20, 30, 40, 50, 60, 75, 90, 120, 150,
180, 210, 240, 260, 280, 300, 360, and 420 min, while the standard sampling
proposed in literature (SS-MTT ) [10], starting from meal ingestion, is t = 0,
10, 20, 30, 60, 90, 120, 150, 180, 240, 300 min. Intravenous lines were then
removed, and the subject had lunch immediately after the end of the study
(∼ 1600÷ 1700), and then a supper (∼ 2000÷ 2030).
Average glucose, C-peptide and insulin concentrations are shown in Fig. 4.1.
Analytical techniques. All blood samples were immediately placed on
ice, centrifuged at 4◦C, separated, and stored at -20◦C until assay. Plasma
glucose concentrations were measured using a glucose oxidase method (YSI,
Yellow Springs, OH). Plasma insulin concentrations were measured by a
chemiluminescence assay with reagents (Access Assay; Beckman, Chaska,
MN). Plasma C-peptide concentrations were measured by radioimmunoas-
say (Linco Research, St. Louis, MO). Body composition was measured using
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dual-energy X-ray absorptiometry (DPX scanner; Lunar, Madison, WI). Vis-
ceral fat was measured by a single-slice computerized tomographic scan at
the level of L2/L3 [34]. This standard procedure was adopted for all the
databases described in this chapter.
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Figure 4.1: Average plasma glucose (a), C-peptide (b), and insulin (c) concen-
trations, in database 1 (vertical bars represent ± SE).
4.3 Database 2: prediabetic subjects
Subjects. 32 subjects (17 women and 15 men) with IFG and 28 subjects
(17 women and 11 men) with NFG participated in the study [8]. All sub-
jects were Caucasian, in good health, at a stable weight, and not involved in
regular vigorous physical exercise. At the time of study, subjects were on no
medications except for a stable dose of thyroid hormone, low-dose aspirin,
hydroxymethylglutaryl-CoA reductase inhibitors, selective serotonin reup-
take inhibitor antidepressants, or antihypertensives, which are considered
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metabolically neutral (e.g., no ACE inhibitors or beta-blockers).
All subjects followed a weight-maintenance diet containing 55% carbohydrate,
30% fat, and 15% protein for at least 3 days before the beginning of the study.
Fasting plasma glucose concentration was measured after an overnight fast on
two separate occasions, at least 1 week apart, in order to classify the subjects:
subjects with average fasting glucose level < 5.2 mmol/l or between 5.6 and
7.0 mmol/l were selected for the study as NFG or IFG, respectively. Subjects
with fasting glucose between 5.2 and 5.6 mmol/l were excluded, since despite
having normal glucose concentrations, it has been demonstrated ([19, 40, 54])
that these individuals have an ∼8% risk of developing diabetes within the
next 10 years and can thus be considered an early form of IFG.
The selected subjects were admitted to the Mayo CRU on two subsequent
occasions at 1700 the evening before the study and ate a standard 10 kcal/kg
meal (55% carbohydrate, 30% fat, and 15% protein) between 1830 and 1900.
No additional food was eaten until the next morning.
OGTT protocol. On one occasion, subjects ingested 75 g glucose after a
12-h overnight fast. Blood was sampled at t = -30, -20, -10, 0, 10, 15, 20,
30, 45, 60, 75, 90, 120, 150, 180, 210, 240 min. Average glucose, C-peptide
and insulin concentrations are shown in Fig. 4.2.
According to these test results, subjects with either NFG or IFG were sub-
classified as NFG/NGT (2-h plasma glucose < 7.8 mmol/l), NFG/IGT (2-h
plasma glucose between 7.8 and 11.1 mmol/l), IFG/IGT, or IFG/diabetes
(2-h plasma glucose > 11.1 mmol/l).
Mixed meal protocol. On a further occasion, subjects ingested a labeled
mixed meal, as described above, according to [5]. Blood samples were col-
lected at t = -30, -20, -10, 0, 5, 10, 15, 20, 30, 40, 50, 60, 75, 90, 120, 150,
180, 210, 240, 260, 280, 300, 360 min. Average glucose, C-peptide and insulin
concentrations are shown in Fig. 4.3.
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Figure 4.2: OGTT average plasma glucose (a), C-peptide (b), and insulin (c)
concentrations, in database 2 (vertical bars represent ± SE).
4.4 Database 3: healthy and T2DM subjects
Subjects. 14 T2DM and 11 healthy subjects participated in the study [4];
all they were in good health, and not regularly engaged in vigorous phys-
ical exercise. Oral antihyperglycemic medications were discontinued 3 weeks
before the study. Two diabetic subjects and one non-diabetic subject were
receiving thyroxine replacement therapy but had normal thyroidstimulating
hormone levels. As usually, all participants had to follow a weight main-
tenance diet for 3 days before the study. At screening, body composition
and visceral fat were measured using dual-energy X-ray absorptiometry and
a single-cut computed tomographic scan.
Mixed meal protocol. Also in this case, subjects ingested a labeled mixed
meal, as described above and represented in [5]. Blood samples were collected
at t = -180, -30, 0, 5, 10, 15, 20, 30, 40, 50, 60, 75, 90, 120, 150, 180,
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Figure 4.3: Mixed meal average plasma glucose (a), C-peptide (b), and insulin
(c) concentrations, in database 2 (vertical bars represent ± SE).
210, 240, 260, 280, 300, 360 min. Average glucose, C-peptide and insulin
concentrations are shown in Fig. 4.4, both for healthy and T2DM subjects.
4.5 Database 4: T2DM subjects
Subjects. 14 subjects with T2DM participated in this study [16]. All they
were in good health, stable weight, not engaged in regular vigorous phys-
ical exercise, and were not treated with medication altering gastric empty-
ing; moreover, they did not have a history of microvascular complications
of diabetes. During the period of the study, the subjects followed the usual
weight-maintenance diet.
Mixed meal protocol. A randomized, double-blind, placebo-controlled
crossover design was utilized: subjects received either 50 mg vildagliptin or
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Figure 4.4: Average plasma glucose (a), C-peptide (b), and insulin (c) concentra-
tions, of healthy () and T2DM subjects (©), in database 3 (vertical bars represent
± SE).
placebo in random order, taken before breakfast and the evening meal over
10 days, in which the two treatments were separated by at least a 2-week
washout period.
Subjects were admitted to the Mayo CRU after 6 days of treatment, in the
evening. Gastric accommodation was measured on the 7th day of the treat-
ment period. Glucose, insulin, and C-peptide concentrations were collected
before and after the ingestion of a mixed meal on day 9.
After an 8-h fast, a forearm vein was cannulated with an 18-gauge needle to
the infusions. An 18-gauge cannula was inserted retrogradely into a vein of
the dorsum of the opposite hand. This was placed in a heated Plexiglas box
maintained at 55◦ C to allow sampling of arterialized venous blood. At t =
-180 min a primed continuous infusion of [6,6-2H2]glucose was initiated. Sub-
jects received a morning dose consisting of 50 mg vildagliptin or placebo at t
= -30 min. At time 0 subjects consumed a meal consisting of two scrambled
eggs labeled with 0.75 mCi 99mTc-sulfur colloid, 55g of Canadian bacon, 240
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ml of water, and Jell-O containing 75 g glucose labeled with [1-13C]glucose
(4% enrichment). This provided 510 kcal (61% carbohydrate, 19% protein,
and 21% fat). Blood was sampled at t = -180, -30, -20, -10, 0, 10, 20, 30,
45, 60, 75, 90, 120, 150, 180, 210, 240, 270, 300, 302, 305, 306, 308, 311,
315, 330, 345, 360 min; the average glucose, C-peptide and insulin data are
shown in Fig. 4.5, both in presence and absence of vildagliptin. To allow a
model-independent assessment of the effect of vildagliptin on insulin action,
5 hours after the start of the study (300 min) subjects received 0.02 unit/kg
body weight of insulin intravenously (over a 5-min period) [16].
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Figure 4.5: Average plasma glucose (a), C-peptide (b), and insulin (c) concentra-
tions, in presence of vildagliptin (), and in presence of placebo (©), in database
4 (vertical bars represent ± SE).
5
Insulin kinetic and HE models
5.1 Introduction
In this chapter, seven models of insulin kinetics and hepatic extraction
are proposed; they include an increasing number of compartments and dif-
ferent novel mechanistic descriptions of HE, each taking into account the
influence of one or more different modifiers, such as plasma glucose and in-
sulin concentrations.
5.2 Insulin kinetic models
Model 1. This model assumes that insulin kinetics is described by a linear
single compartment (see Fig. 5.1, top panel), according to the Model of Data
[11] described in chapter 3:
I˙(t) = −n · I(t) + IDR(t)/VI (5.1)
Indexes of HE can easily be obtained: for HEb and HEtot Eq. (3.36) and
(3.35) are used.
Model 2. This model assumes a two-compartment description of insulin
kinetics (see Fig. 5.1, middle panel), similarly to what reported in [26], and
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later in [17]:
I˙L(t) = −[m1 +m3(t)] · IL(t) +m2 · IP (t) + ISR(t)
(VP ·BW ) IL(0) = ILb
(5.2)
I˙P (t) = −(m2 +m4) · IP (t) +m1 · IL(t) IP (0) = IPb
(5.3)
I(t) = IP (t) (5.4)
where IL, IP (pmol/l) are insulin concentrations in liver and plasma, respect-
ively; I (pmol/l) is measured plasma insulin concentration; ISR (pmol/min)
is insulin secretion rate; VP is the volume of insulin distribution (l/kg); m1,
m2, m4, (min−1) are rate parameters; m3 (min−1) is a time-varying para-
meter which, as in [17], is:
m3(t) =
HE(t) ·m1
1−HE(t) (5.5)
According to Eq. (5.2)-(5.3), in basal state, one has:
ILb =
m2 · IPb + ISRb/(BW · VP )
m1 +m3(0)
(5.6)
IPb = Ib (5.7)
where:
m3(0) =
HEb ·m1
1−HEb (5.8)
HEb can be calculated from Eq. (5.3), using the steady state constraints:
HEb =
ISRb/(BW · VP )−m4 · IPb
ISRb/(BW · VP ) +m2 · IPb (5.9)
while HEtot is defined from Eq. (5.5) as follows:
HEtot =
∫ T
0
m3(t)dt∫ T
0
(m3(t) +m1)dt
(5.10)
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Figure 5.1: Model 1 (top panel), Model 2 (middle panel), Model 3 (bottom
panel). I (pmol/l), plasma insulin concentration, accessible to measurement; n
(min−1), fractional insulin clearance rate; ISR (pmol/min), insulin secretion rate;
IDR (pmol/min), posthepatic insulin delivery rate; IL, IP and IEV (pmol/l), in-
sulin concentrations in the liver, plasma and extravascular space, respectively; m1,
m2, m4, m5, m6 (min
−1), rate parameters; m3 (min−1), time-varying parameter
dependent on hepatic insulin extraction HE (%).
Model 3. This model assumes a more physiological three-compartment
description of insulin kinetics (see Fig. 5.1, bottom panel) across the liver,
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plasma and extra-vascular space, according to [44]:
I˙L(t) = −[m1 +m3(t)] · IL(t) +m2 · IP (t) + ISR(t)
(VP ·BW ) IL(0) = ILb
(5.11)
I˙P (t) = −(m2 +m4 +m5) · IP (t) +m1 · IL(t) +m6 · IEV (t) IP (0) = IPb
(5.12)
I˙EV (t) = −m6 · IEV (t) +m5 · IP (t) IEV (0) = IEV b
(5.13)
I(t) = Ip(t) (5.14)
where, compared to Model 2, IEV (pmol/l), i.e. insulin concentration in the
extra-vascular space, as well as the rate parameters m5 and m6 (min−1), have
been added.
Eq. (5.5)÷(5.8) from Model 2 are still valid, and for IEV , in basal state, one
has:
IEV b =
m5
m6
· IPb (5.15)
For HEb and HEtot the same formulations shown in Eq. (5.9)-(5.10) hold.
5.3 HE models
As explained in chapter 3, HE has been described by Campioni et al. as a
piecewise linear function [11] during a meal tolerance test. This is a Model of
Data which allows reconstruction of the HE profile from plasma C-peptide,
insulin and glucose concentrations and provides an index of overall hepatic
extraction, without assuming any mechanistic description of the phenomena
controlling hepatic function.
Once its profile is reconstructed, it is easy to observe that, during an
oral test, HE decreases when glucose and insulin concentrations rise (see Fig.
4 in [11]). Prior observations suggest that nutrient intake modifies hepatic
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extraction of insulin [31, 41], and glucose ingestion both stimulates insulin
secretion and reduces hepatic fractional extraction [21]. While this was ini-
tially attributed to incretin signaling by the gut, this does not seem to be
the case [39]. Indeed, Pivarova et al. [42] have demonstrated that insulin
degrading enzyme (IDE) activity is inhibited by hyperglycemia and hyper-
insulinemia. Therefore, we attempted to describe HE as a linear function of
plasma glucose and insulin alone, and combined.
Here, three different HE descriptions are proposed, each taking into ac-
count the influence of one or more different modifiers: plasma glucose and
insulin concentrations alone, as well as in combination.
Model a. This model assumes HE to be linearly dependent on plasma
glucose concentration G (mmol/l):
HE(t) = −aG ·G(t) + a0G HE(0) = HEb (5.16)
where aG (l/mmol) is a parameter representing the control of plasma glucose
on hepatic insulin extraction, and a0G (dimensionless) is obtained from the
steady state constraint:
a0G = HEb + aG ·Gb (5.17)
An index accounting for glucose control on HE can be derived from the
model parameters; in fact, it easy to define the sensitivity of HE to glucose
concentration SHEG (l/mmol) as follows:
SHEG = −
∂HE(t)
∂G
∣∣∣∣
SS
= aG (5.18)
Model b. This model assumes HE to be dependent on plasma insulin con-
centration I (pmol/l):
HE(t) = −aI · I(t) + a0I HE(0) = HEb (5.19)
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where aI (l/pmol) is a parameter representing the control of insulin on HE,
and a0I (dimensionless) is obtained from the steady state constraint:
a0I = HEb + aI · Ib (5.20)
In this case, an index describing HE sensitivity to insulin, i.e. SHEI , can be
derived:
SHEI = −
∂HE(t)
∂I
∣∣∣∣
SS
= aI (5.21)
Model c. This model assumes HE to be dependent on both plasma insulin
and glucose concentrations:
HE(t) = −aG ·G(t)− aI · I(t) + a0GI HE(0) = HEb (5.22)
where a0GI (dimensionless) is easily obtained from:
a0GI = HEb + aG ·Gb + aI · Ib (5.23)
SHEG and S
HE
I are derived using Eq. (5.18)-(5.21).
5.4 Models of System
Combining the insulin kinetic models listed in paragraph 5.2 with every
HE description provided in paragraph 5.3, it would be possible to obtain nine
different Models of System. However, the HE description corresponding to
Model c is presented here only for the single-compartment insulin kinetics,
since, as highlighted later in chapter 6, this HE formulation makes the model
unable to adequately estimate insulin parameters, most likely because of the
similarity between glucose and insulin oral trends, which makes numerical
identification of the model difficult. That is why here just seven models are
presented:
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1. Model I, obtained from Model 1 of insulin kinetics and Model a of HE
(see Fig. 5.2, top panel).
2. Model II, obtained from Model 1 of insulin kinetics and Model b of
HE (see Fig. 5.2, middle panel).
3. Model III, obtained from Model 1 of insulin kinetics and Model c of
HE (see Fig. 5.2, bottom panel).
4. Model IV, obtained from Model 2 of insulin kinetics and Model a of
HE (see Fig. 5.3, top panel).
5. Model V, obtained from Model 2 of insulin kinetics and Model b of
HE (see Fig. 5.3, bottom panel).
6. Model VI, obtained from Model 3 of insulin kinetics and Model a of
HE (see Fig. 5.4, top panel).
7. Model VII, obtained from Model 3 of insulin kinetics and Model b of
HE (see Fig. 5.4, bottom panel).
For C-peptide secretion and kinetics, the model described at the begin-
ning of paragraph 3.2.2 [10, 24] is used, thus, both C-peptide and insulin
data are predicted simultaneously.
In Table 5.1, the main features of the insulin models (number of com-
partments, HE descriptions and indexes) are summarized, for readers con-
venience.
5.5 Model identification
5.5.1 A priori identifiability
All the proposed models are globally identifiable, if the parameter m2 is
assumed to be known inModels IV, V, VI, VII, according to DAISY software
[7].Parameter m2 becomes identifiable when an external input enters the
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Figure 5.2: Model I (top panel), Model II (middle panel), Model III (bottom
panel).
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plasma insulin compartment (see par. 7.4).
DAISY is a computer tool, implementing a differential algebra algorithm
used to automatically perform the parameter identifiability analysis, both
for linear and nonlinear dynamic models, described by differential equations.
In this case, it was particularly useful because of the nonlinearity in Eq.
(5.5), that made a manual calculation complicated to solve.
5.5.2 Numerical identification
C-peptide and insulin models were identified in all the subjects by non-
linear weighted least squares [13] implemented in Matlab. If some paramet-
ers provided a poor estimation precision, a Maximum A Posteriori (MAP)
Bayesian estimator approach was adopted. Error on C-peptide and insulin
measurements was assumed to be independent, Gaussian, with zero mean
and variance dependent to the C-peptide and insulin measurements, respect-
ively, as reported in [50]:
var(Cp) = 2000 + 0.001 · Cp2 (5.24)
var(I) = 6 + 0.0055 · I2 (5.25)
Glucose is the model forcing function, thus it is assumed to be known without
error.
As mentioned in chapter 3, the simultaneous estimation of both secretion
and kinetics is possible thanks to the method proposed by Van Cauter [55]:
in particular the C-peptide kinetic parameters (k01, k21, k12, Vc) are fixed,
according to the following population models:
k12 = FRA ·B1 + (1− FRA) · A1 (5.26)
k01 =
A1 ·B1
k12
(5.27)
k21 = A1 +B1− k12 − k01 (5.28)
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Vc =
BSA · 1.92 + 0.64 ifsex = MBSA · 1.11 + 2.04 ifsex = F (5.29)
where:
AB = 0.14 · age+ 29.16 (5.30)
B1 =
ln2
AB
(5.31)
FRA =
0.78 ifBMI > 270.76 ifBMI ≤ 27 (5.32)
A1 =
0.52 ifBMI > 270.14 ifBMI ≤ 27 (5.33)
For the Model of Data, as hinted in chapter 3, Campioni et al. [11] had
to develop linear regression models linking CLI and VI to anthropometric
characteristics, in order to be able to fix VI and n, and to just estimate the
HE breakpoints:
ln(VI) = 0.814 + 0.754 ·BSA− 0.000908 · age (5.34)
ln(CLI) = −0.0402 + 0.372 ·BSA− 0.00313 · age (5.35)
Eq. (5.34)-(5.35) were also used for all the other single-compartment insulin
kinetic descriptions (Model I, II, III ).
In Model IV, V, VI, VII, all the insulin kinetic parameters are estimated,
except for m2, which is fixed to 0.268 min−1, as suggested in [27], and done
in [44].
5.6 Statistical analysis
Data are presented as mean±SD, unless otherwise stated. Pearson's lin-
ear correlation was adopted to evaluate univariate correlation. Two samples
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paired and unpaired comparisons were undertaken using nonparametric and
T-test (depending on the outcome of the gaussianity test of each distribu-
tion).
5.7 Model selection
The best model selected among Model of Data, Model I, Model II, Model
of III, Model IV, Model V, Model VI, Model VII, is chosen by comparing
model performances on the basis of different criteria: residual independence
(Anderson Run Test), precision of parameters estimates (expressed as percent
coefficient of variation, CV%), ability to describe the data (weighted residual
square sum, WRSS), and model parsimony (Akaike Information Criterion,
AIC), here calculated as follows:
AIC = WRSS + 2P (5.36)
where P is the number of estimated parameters.

6
Model assessment in database 1
6.1 Introduction
In this chapter, the models are assessed using database 1. Results of the
simultaneous identification of oral C-peptide minimal model and each insulin
kinetic model (Model of Data, Model I, Model II, Model III, Model IV, Model
V, Model VI, Model VII ) are presented. Then, after selecting the optimal
model among them, the reconstructed HE profiles and indexes are shown.
Finally, a comparison between the frequent and standard sampling condition
is provided.
6.2 Model selection
The time courses of weighted residuals, obtained with the previously pub-
lished Model of Data and with the new tested models, are reported in Fig.
6.1÷6.8 (C-peptide and insulin, top and bottom panel, respectively).
Results of the model comparison are summarized in Table 6.1, both for
the C-peptide and insulin sub-models.
Models IV, V have been discarded, because randomness of the insulin weighted
residuals is supported by the Run Test in only 59% and 67%, of the cases,
respectively, and the estimated parameters, especially those of the C-peptide
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Figure 6.1: Average C-peptide (top panel) and insulin (bottom panel) weighted
residuals for Model of Data (vertical bars represent ± SD).
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Figure 6.2: Average C-peptide (top panel) and insulin (bottom panel) weighted
residuals for Model I (vertical bars represent ± SD).
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Figure 6.3: Average C-peptide (top panel) and insulin (bottom panel) weighted
residuals for Model of II (vertical bars represent ± SD).
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Figure 6.4: Average C-peptide (top panel) and insulin (bottom panel) weighted
residuals for Model III (vertical bars represent ± SD).
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Figure 6.5: Average C-peptide (top panel) and insulin (bottom panel) weighted
residuals for Model IV (vertical bars represent ± SD).
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Figure 6.6: Average C-peptide (top panel) and insulin (bottom panel) weighted
residuals for Model V (vertical bars represent ± SD).
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Figure 6.7: Average C-peptide (top panel) and insulin (bottom panel) weighted
residuals for Model VI (vertical bars represent ± SD).
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Figure 6.8: Average C-peptide (top panel) and insulin (bottom panel) weighted
residuals for Model VII (vertical bars represent ± SD).
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model, show the poor precision (high CV).
Models III, VII were also discarded, because parameters were estimated with
poor precision.
For what concerns the remaining models, that are Model of Data, Models
I, II and VI, Model I and Model II have been discarded since whiteness of
weighted residuals was not strongly supported by the Anderson Run Test
(see also Fig. 6.2-6.3). Model of Data and Model VI can fit data and provide
good precision of parameter estimates, but AIC index shows that Model VI
is the most parsimonious (AICC−peptide=156±100 and AICInsulin=136±57),
meaning that it provides the best compromise between model complexity and
ability to fit the data.
It is of note that, however, the average weighted residuals of Model VI are
not random at the beginning of the test. C-peptide is slightly over-fitted (see
Fig. 6.7, top panel), but this also happens with the Model of Data (see Fig.
6.1, top panel), and thus Model VI remains superior, in terms of parsimony.
As regards insulin, in t = 15, 20, 30 min, there is a sort of under-fitting,
on average (see Fig. 6.7, bottom panel), but this is due to a small subset of
subjects (approximately 5%).
The parameter estimates and precision provided by the selected model are
shown in Table 6.2.
As mentioned above, Model VI includes three compartments of insulin
kinetics; this particular description is more physiological, when compared to
the single and two-compartment models, since it considers plasma, liver and
extravascular spaces, as well as the exchange fluxes linking them. In fact, the
presence of a second insulin compartment, besides that in plasma, has been
initially proposed in [26], and later demonstrated in [25, 47], where insulin
first in dogs and then in humans, was assumed to traverse the capillary
endothelial barrier in both directions (plasma-interstitial spaces). Thus, in
order to provide a realistic description of insulin extraction mediated by the
liver, here the chosen model includes a hepatic compartment, as described
even in [17], thus adopting the existing three-compartment description of
insulin kinetics shown in [44].
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Table 6.2: Parameter estimates and precision (CV), obtained with Model VI.
Parameters Units Estimates CV
(mean±SD) (%)
VP (l/kg) 0.057±0.021 30
aG (l/mmol) 0.144±0.064 15
m4 (min−1) 0.335±0.178 14
m5 (min−1) 0.283±0.116 20
m6 (min−1) 0.018±0.008 21
m1 (min−1) 0.946±0.424 34
α (min−1) 0.091±0.085 11
Φd (10−9) 558.3±236.0 7
Φs (10−9 min−1) 34.24±12.50 3
h (mmol/l) 4.690±0.523 2
6.3 Reconstructed HE profiles
The selected model, i.e., Model VI, allows reconstruction of individual
HE profiles. The resulting average HE is shown in Fig. 6.9 together with
that provided by the Model of Data, and thus included in the literature [11].
Evidently, HE decreases more rapidly and to a greater extent with the Model
VI, than with the Model of Data; in addition, the new profile returns to its
basal state at the end of the experiment, as would be expected 420 minutes
after meal ingestion. This difference can be explained by observing that the
HE expression of the Model of Data consists of a piecewise linear function
with seven breakpoints, which make the model vulnerable to noise. On the
other hand, the description of HE proposed in Model VI is a linear function
of plasma glucose concentration, thus the end-test steady state is guaranteed
insofar as plasma concentrations have returned to basal. It is also remarkable
that these two profiles are obtained from two completely different models of
insulin kinetics, as explained above, which of course yield different HE results.
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Figure 6.9: Average HE profile of Model of Data (©) and Model VI ().
6.4 HE indexes
The basal (HEb) and total (HEtot) hepatic insulin extraction indexes
obtained with Model VI [Eq. (5.9)-(5.10)] and with the Model of Data [Eq.
(3.36)-(3.35)] have been compared. The basal average values differ signific-
antly [HEModelofDatab = 0.617±0.090, HEModelV Ib = 0.710±0.109, p < 0.0001;
see Fig. 6.10, (a)]. This is due to the fact that, in Model VI, HEb also de-
pends on m4, that is one of the estimated parameters, while in the Model of
Data, the same index is calculated from population values and basal measure-
ments. Similarly, the total hepatic extraction index is significantly different
in the two cases [HEModelofDatatot = 0.435±0.145, HEModelV Itot = 0.655±0.139,
p = 0.0001; see Fig. 6.10, (b)], as one could expect, since HEb calculation,
the insulin kinetics and the HE descriptions are different, too.
Moreover, it has been assessed whether model derived indexes were differ-
ent in young (Y) and elderly (E) people, similarly to what reported in [6].
Our results show that HEb and HEtot did not significantly differ in E com-
pared to Y people [HEb = 0.703±0.116 vs. 0.728±0.091, p > 0.05; HEtot =
0.646±0.119 vs. 0.677±0.146, respectively, p > 0.05; see Fig. 6.11, (a), (c),
respectively], while SHEG was significanlty lower in E vs. Y subjects [S
HE
G =
0.136±0.062 vs. 0.164±0.065 l/mmol, respectively, p < 0.05; see Fig. 6.11,
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(e)].
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Figure 6.10: HEb (a) and HEtot (b) indexes, derived from Model of Data, and
Model VI. * p < 0.05.
6.5 Frequent sampling vs. standard sampling
The new model performed well even if data of a standard [10] (SS ),
instead of a frequently sampled [6] (FS ), MTT are used (see Fig. 6.12 for the
corresponding time grids). Results are shown in Table 6.3. Run Test confirms
that SS weighted residuals are random in quite all the subjects, and the
WRSS values, normalized according to the number of samples (nWRSS), are
comparable with those obtained with the FS-MTT. Moreover, the precision
of parameter estimates is still good, despite the loss of 10 time samples.
HE indexes obtained using the SS and FS-MTT (see average estimates in
Table 6.4) are well correlated, as evident from Fig. 6.13 (R=0.77, p<0.0001
for HEb; R=0.77, p<0.0001 for HEtot; R = 0.61, p < 0.0001 for SHEG ).
Furthermore, SHEG was still significantly lower in E vs. Y when estimated with
the SS-MTT [SHEG = 0.172±0.080 vs. 0.196±0.092 l/mmol, p < 0.05; see Fig.
6.11, (f)], while no difference was revealed in HEb [HEb = 0.722±0.174 vs.
0.743±0.142, p > 0.05; see Fig. 6.11, (b)] and HEtot [HEtot = 0.641±0.146
vs. 0.685±0.119, p > 0.05; see Fig. 6.11, (d)], confirming the results provided
by the FS-MTT.
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Figure 6.11: Indexes of basal hepatic insulin extraction, HEb, (a, b), total hep-
atic insulin extraction, HEtot, (c, d), and hepatic insulin extraction sensitivity to
glucose, SHEG , (e, f), derived from Model VI in elderly and young subjects (E and
Y, respectively), using frequent sampling (FS-MTT) (left) and standard sampling
(SS-MTT) (right). * p < 0.05.
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Figure 6.12: FS- and SS-MTT sampling grids.
Table 6.3: Model VI: comparison between FS and SS-MTT.
N◦ of Run Test Precision nWRSS
samples (mean CV) (mean±SD)
C-peptide
FS-MTT 21 93% 6% 7±5
SS-MTT 11 97% 13% 8±14
Insulin
FS-MTT 21 98% 22% 6±3
SS-MTT 11 97% 27% 5±6
Table 6.4: HE indexes in FS- vs. SS-MTT.
Index Units FS-MTT estimates FS-MTT estimates
(mean±SD) (mean±SD)
HEb (dimensionless) 0.710±0.109 0.729±0.108
HEtot (dimensionless) 0.655±0.139 0.655±0.166
SHEG (l/mmol) 0.144±0.064 0.180±0.085
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7.1 Introduction
In this chapter Model VI, selected in the previous chapter as the most
parsimonious one in a database of healthy subjects, is employed to assess
its performance in all the spectrum of glucose tolerance. To this purpose,
we used database 2, made up of prediabetic subjects who underwent both a
MTT and an OGTT, database 3, made up of healthy and T2DM subjects,
and database 4, made up of T2DM subjects.
7.2 Database 2
As explained in chapter 4, the prediabetic subjects within database 2
underwent a MTT, as well as an OGTT. In the following paragraphs, the
model performances in both these tests are presented.
7.2.1 Meal
Model VI can well predict both C-peptide and insulin MTT data of
database 2 [8], as evident from the average weighted residuals shown in Fig.
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7.1 (C-peptide and insulin, top and bottom panel, respectively). Moreover,
it provides precise estimates of the parameters (see Table 7.1).
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Figure 7.1: Average C-peptide (top panel) and insulin (bottom panel) weighted
residuals, in database 2, during meal (vertical bars represent ± SD).
Table 7.1: Parameter estimates and precision (CV), in database 2, during meal.
Parameters Units Estimates CV
(mean±SD) (%)
VP (l/kg) 0.049±0.023 48
aG (l/mmol) 0.140±0.069 25
m4 (min−1) 0.333±0.112 18
m5 (min−1) 0.279±0.105 25
m6 (min−1) 0.017±0.010 22
m1 (min−1) 1.229±0.529 54
α (min−1) 0.089±0.061 12
Φd (10−9) 625.9±325.3 9
Φs (10−9 min−1) 36.86±13.07 3
h (mmol/l) 4.733±0.543 4
Another interesting result concerns the difference found in HE profiles
and indexes, in NGT (n=25) vs. IFG/IGT (n=16) subjects (see correspond-
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ing data in Fig. 7.2). The HE profile is lower in IFG/IGT, on average (Fig.
7.3). The statistical tests confirm that HEb and HEtot indexes are higher
in NGT than IFG/IGT subjects (HEb = 0.626±0.137 vs. 0.532±0.137, p <
0.05; HEtot = 0.613±0.192 vs. 0.491±0.137, p < 0.05, respectively) (see
Fig. 7.4), while no difference is found in SHEG (S
HE
G = 0.155±0.070 vs.
0.140±0.050 l/mmol, p > 0.05, respectively). These results are congruent
with the plasma concentration profiles shown in Fig. 7.2, since plasma gluc-
ose is higher in IFG/IGT than NGT.
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Figure 7.2: Average plasma glucose (a), C-peptide (b), and insulin (c) concentra-
tions of NGT (©) and IFG/IGT () subjects, in database 2, during meal (vertical
bars represent ± SE).
7.2.2 Oral Glucose Tolerance Test (OGTT)
The model, originally developed for a MTT, has also been used in the
OGTT data of the same prediabetic subjects composing database 2. As
shown by the average weighted residuals plotted in Fig. 7.5, the model can
adequately predict C-peptide data, even during the OGTT. Evidently from
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Figure 7.3: Average HE profiles of NGT (©) and IFG/IGT () subjects, in
database 2, during meal.
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Figure 7.4: Average HEb (a), HEtot (b), and S
HE
G (c) indexes of NGT and
IFG/IGT subjects, in database 2, during meal. * p < 0.05.
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this figure, insulin seems not to be well fitted, on average, in t = 20 min, and
this is due to approximately 10% of the subjects.
Given that, during the OGTT, the time grid is shorter and under-sampled
compared to the MTT (see paragraph 4.3), in this case it was necessary to
use a Bayesian approach in order to improve the precision of the parameter
estimates, in approximately 20% of the subjects, especially for the parameters
VP and α, included, respectively, in the insulin and C-peptide kinetics; this
may in part explain the worsening of model fit in t = 20 min. The mean and
SD used in the MAP estimator for these two parameters are, respectively:
VP : mean(VP ) = 0.04, SD(VP ) = 0.2 ·mean(VP ) (7.1)
α : mean(α) = 0.09, SD(α) = 0.5 ·mean(α) (7.2)
where, for VP , the mean value was chosen by considering the estimate res-
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Figure 7.5: Average C-peptide (top panel) and insulin (bottom panel) weighted
residuals, in database 2, during OGTT (vertical bars represent ± SD).
ulting from the meal test, and a SD corresponding to 20% of the mean was
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shown to be sufficient, while, for α, mean and SD are the ones typically used
in the oral C-peptide minimal model, when needed.
The OGTT parameter estimates and CV are shown in Table 7.2, demon-
strating the good model performance also in this case.
Unlike what happened during the MTT, in the OGTT the HE indexes
did not differ between NGT and IFG/IGT. A possible explanation can be
found in the different nutrients that affect the MTT and OGTT insulin se-
cretion and clearance. In particular, it has been shown that amino acids may
stimulate insulin secretion [9], and that free fatty acids may directly interfere
with insulin clearance [21, 32]. Our results indicate that the effect of other
nutrients on HE may be different in healthy and prediabetic subjects.
Table 7.2: Parameter estimates and precision (CV), in database 2, during OGTT.
Parameters Units Estimates CV
(mean±SD) (%)
VP (l/kg) 0.056±0.046 37
aG (l/mmol) 0.138±0.098 18
m4 (min−1) 0.468±0.360 30
m5 (min−1) 0.155±0.115 40
m6 (min−1) 0.013±0.009 50
m1 (min−1) 0.917±0.750 32
α (min−1) 0.113±0.115 20
Φd (10−9) 568.4±325.5 13
Φs (10−9 min−1) 28.88±12.11 6
h (mmol/l) 5.264±1.062 4
7.3 Database 3
As highlighted in chapter 4, database 3 is made up of 14 T2DM and 11
healthy subjects. In the following paragraphs the model performances are
shown in both these groups, then focusing on the comparison of HE results.
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7.3.1 Healthy subjects
Model VI can quite well predict both C-peptide and insulin data in
the healthy subjects composing database 3 [4], as evident from the aver-
age weighted residuals shown in Fig. 7.6 (C-peptide and insulin, top and
bottom panel, respectively). Moreover, the model can precisely estimate the
parameters (see Table 7.3).
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Figure 7.6: Average C-peptide (top panel) and insulin (bottom panel) weighted
residuals of healthy subjects, in database 3 (vertical bars represent ± SD).
7.3.2 T2DM subjects
Model VI can comprehensively well predict both C-peptide and insulin
data also in the T2DM subjects composing database 3 [4], as shown by the
average weighted residuals in Fig. 7.7 (C-peptide and insulin, top and bottom
panel, respectively). However, the average C-peptide and insulin weighted
residuals do not always appear to be random.
The parameters are precisely estimated, even if, on average, the CV are a
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Table 7.3: Parameter estimates and precision (CV) of healthy subjects, in data-
base 3.
Parameters Units Estimates CV
(mean±SD) (%)
VP (l/kg) 0.028±0.008 16
aG (l/mmol) 0.113±0.049 13
m4 (min−1) 0.534±0.285 17
m5 (min−1) 0.257±0.085 27
m6 (min−1) 0.014±0.008 29
m1 (min−1) 1.214±0.596 27
α (min−1) 0.188±0.166 26
Φd (10−9) 672.8±252.0 7
Φs (10−9 min−1) 45.48±12.80 2
h (mmol/l) 4.637±0.432 1
bit higher in this group, compared to healthy subjects, as it usually happens
(see Table 7.4).
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Figure 7.7: Average C-peptide (top panel) and insulin (bottom panel) weighted
residuals of T2DM subjects, in database 3 (vertical bars represent ± SD).
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Table 7.4: Parameter estimates and precision (CV) of T2DM subjects, in database
3.
Parameters Units Estimates CV
(mean±SD) (%)
VP (l/kg) 0.038±0.019 38
aG (l/mmol) 0.080±0.047 18
m4 (min−1) 0.705±0.401 38
m5 (min−1) 0.193±0.172 43
m6 (min−1) 0.021±0.010 43
m1 (min−1) 0.635±0.761 28
α (min−1) 0.030±0.035 14
Φd (10−9) 311.1±263.9 13
Φs (10−9 min−1) 18.29±9.63 12
h (mmol/l) 6.489±3.226 17
7.3.3 Healthy vs. T2DM subjects
In the matter of HE in healthy vs. T2DM subjects, the average profiles
representing these two groups differ significantly (see Fig. 7.8): the basal
level, as well as the whole curve, is lower in T2DM, confirming what was
expected, i.e. that HE is reduced when the pathology level increases.
These observations are even more evident when considering the HE indexes,
represented in Fig. 7.9, where HEb, HEtot, and also SHEG are significantly
higher in healthy then T2DM subjects (HEb = 0.655±0.135 vs. 0.386±0.149,
p < 0.05; HEtot = 0.574±0.199 vs. 0.195±0.130, p < 0.05; SHEG = 0.113±0.049
vs. 0.080±0.049 l/mmol, p < 0.05, respectively).
7.4 Database 4
As mentioned in chapter 4, 14 T2DM subjects were studied after the
administration of vildagliptin or placebo, received in random order [16]. The
peculiarity of this protocol is the intravenous insulin infusion (0.02 unit/kg
of BW) that was administrated over a 5-min period, starting at t=300 min,
in order to allow a better estimate of insulin kinetic parameters.
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Figure 7.8: Average HE profiles of healthy () and T2DM (©) subjects, in
database 3.
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Figure 7.9: Average HEb (a), HEtot (b), and S
HE
G (c) indexes of healthy and
T2DM subjects, in database 3. * p < 0.05.
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This allowed performance of two different identifications, and comparison of
the results. The first identification includes all the data samples in 0 ÷ 360
min, while the second one just employs the data collected before the insulin
infusion, i.e. 0÷ 300 min.
7.4.1 Identification in [0÷ 360] min
Model VI can fit C-peptide and insulin data reasonably well in database 4
[16], both after placebo and vildagliptin administration (see average weighted
residuals in Fig. 7.10-7.11, C-peptide and insulin, top and bottom panel,
respectively). Obviously, the insulin infusion starting in t = 300 min made
it difficult to fit the insulin sample drawn at t = 302 min, which is discarded
when it falls in a rapid rising edge, in order to improve the whole fit; this
fact is responsible for the very low value of insulin weighted residuals at that
time point.
The parameters are precisely estimated in both the cases, as shown in Tables
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Figure 7.10: Average C-peptide (top panel) and insulin (bottom panel) weighted
residuals, in database 4 after placebo administration (identification in 0÷360 min;
vertical bars represent ± SD).
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Figure 7.11: Average C-peptide (top panel) and insulin (bottom panel) weighted
residuals, in database 4 after vildagliptin administration (identification in 0÷ 360
min; vertical bars represent ± SD).
7.5-7.6. Thanks to the peculiarity of this protocol, which includes the insulin
infusion, it was also possible to well estimate the parameter m2, that was
usually fixed to a standard value (m2 = 0.268 min−1, in database 1, 2, 3 ).
The average HE profiles are very similar after placebo and vildagliptin
administration (Fig. 7.12). This observation is strengthened by the statist-
ical tests performed on the HE indexes (see Fig. 7.13): no significant differ-
ence is found in presence of placebo or vildagliptin (HEb = 0.433±0.162 vs.
0.467±0.196, p > 0.05; HEtot = 0.370±0.195 vs. 0.394±0.234, p > 0.05; SHEG
= 0.076±0.48 vs. 0.094±0.57 l/mmol, p > 0.05, respectively), confirming the
results found in the previous work [16], using the Model of Data.
7.4.2 Identification in [0÷ 300] min
Just identifying the first 300 minutes of the protocol, i.e. excluding the
insulin infusion, Model VI can adequately predict the data (see Fig. 7.14-
7.15) and the parameters are estimated with a good precision (see Tables
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Table 7.5: Parameter estimates and precision (CV), in database 4 after placebo
administration (identification in 0÷ 360 min).
Parameters Units Estimates CV
(mean±SD) (%)
VP (l/kg) 0.061±0.019 8
aG (l/mmol) 0.076±0.048 18
m4 (min−1) 0.474±0.245 14
m5 (min−1) 0.345±0.095 56
m6 (min−1) 0.084±0.073 47
m1 (min−1) 0.652±0.503 56
m2 (min−1) 0.356±0.496 36
α (min−1) 0.051±0.035 23
Φd (10−9) 205.2±198.1 58
Φs (10−9 min−1) 17.89±13.80 7
h (mmol/l) 5.456±1.622 9
Table 7.6: Parameter estimates and precision (CV), in database 4 after
vildagliptin administration (identification in 0÷ 360 min).
Parameters Units Estimates CV
(mean±SD) (%)
VP (l/kg) 0.062±0.034 7
aG (l/mmol) 0.094±0.057 17
m4 (min−1) 0.410±0.153 13
m5 (min−1) 0.381±0.058 24
m6 (min−1) 0.071±0.061 30
m1 (min−1) 0.594±0.438 54
m2 (min−1) 0.394±0.438 43
α (min−1) 0.050±0.031 16
Φd (10−9) 226.9±164.0 16
Φs (10−9 min−1) 17.58±9.248 7
h (mmol/l) 5.946±2.561 6
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Figure 7.12: Average HE profiles in database 4 after placebo () and vildagliptin
(©) administration (identification in 0÷ 360 min).
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Figure 7.13: Average HEb (a), HEtot (b), and S
HE
G (c) indexes in database 4 after
placebo and vildagliptin administration (identification in 0÷ 360 min).
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7.7-7.8), in the presence of placebo and vildagliptin. As expected, the CV
are higher on average if compared to the ones shown in Tables 7.5-7.6, because
of the absence of insulin infusion.
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Figure 7.14: Average C-peptide (top panel) and insulin (bottom panel) weighted
residuals, in database 4 after placebo administration (identification in 0÷300 min;
vertical bars represent ± SD).
Table 7.7: Parameter estimates and precision (CV), in database 4 after placebo
administration (identification in 0÷ 300 min).
Parameters Units Estimates CV
(mean±SD) (%)
VP (l/kg) 0.062±0.022 34
aG (l/mmol) 0.112±0.069 24
m4 (min−1) 0.446±0.233 42
m5 (min−1) 0.262±0.163 51
m6 (min−1) 0.020±0.015 63
m1 (min−1) 1.059±0.849 42
α (min−1) 0.043±0.021 25
Φd (10−9) 237.2±125.5 30
Φs (10−9 min−1) 17.18±10.03 12
h (mmol/l) 6.311±2.413 13
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Figure 7.15: Average C-peptide (top panel) and insulin (bottom panel) weighted
residuals, in database 4 after vildagliptin administration (identification in 0÷ 300
min; vertical bars represent ± SD).
Table 7.8: Parameter estimates and precision (CV), in database 4 after
vildagliptin administration (identification in 0÷ 300 min).
Parameters Units Estimates CV
(mean±SD) (%)
VP (l/kg) 0.046±0.021 13
aG (l/mmol) 0.105±0.062 24
m4 (min−1) 0.473±0.247 25
m5 (min−1) 0.236±0.162 33
m6 (min−1) 0.011±0.004 73
m1 (min−1) 0.973±0.786 64
α (min−1) 0.038±0.015 15
Φd (10−9) 301.0±119.7 23
Φs (10−9 min−1) 22.59±7.970 10
h (mmol/l) 6.735±2.979 7
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As regards HE, the average profiles, in the presence of placebo and
vildagliptin, are reported in Fig. 7.16. In this case, the average vildagliptin
profile seems a bit higher than observed with placebo, whereas in "0÷360
min" the difference was quite imperceptible. However, the statistical tests
performed on HE indexes (see Fig. 7.17) show no significant difference in
placebo vs. vildagliptin (HEb = 0.471±0.187 vs. 0.566±0.123, p > 0.05;
HEtot = 0.362±0.249 vs. 0.418±0.228, p > 0.05; SHEG = 0.112±0.069 vs.
0.105±0.062 l/mmol, p > 0.05, respectively).
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Figure 7.16: Average HE profiles in database 4, after placebo () and vildagliptin
(©) administration (identification in 0÷ 300 min).
7.4.3 Comparison
The HE indexes obtained in both the identifications performed in data-
base 4 ("0÷ 360 min" and "0÷ 300 min") were compared in order to assess
how much the optimal estimate of insulin kinetics may change the results
obtained in sub-obtimal conditions (see average values in Table 7.9). It is of
note that, for this kind of analysis, all the subjects were considered together,
no matter of placebo or vildagliptin administration, for the purpose of in-
creasing the power of the test.
In Fig. 7.18 the correlation analysis performed on HEb, HEtot, SHEG and
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Figure 7.17: Average HEb (a), HEtot (b), and S
HE
G (c) indexes in database 4 after
placebo and vildagliptin administration (identification in 0÷ 300 min).
insulin clearance (CLI = m4 · VP ) are shown, and, clearly, all these indexes
provide a significant correlation between the two cases (R = 0.57, p < 0.005
for HEb; R = 0.70, p < 0.005, for HEtot; R = 0.84, p < 0.005, for SHEG ; R
= 0.87, p < 0.005, for CLI). This result confirms that Model VI does not
need the use of an exogenous insulin infusion in order to obtain reliable HE
oral indexes.
Table 7.9: HE indexes in "0÷ 300 min" vs. "0÷ 360 min" identification.
Index Units "0÷ 300 min" estimates "0÷ 360 min" estimates
(mean±SD) (mean±SD)
HEb (dimensionless) 0.519±0.163 0.450±0.176
HEtot (dimensionless) 0.390±0.235 0.382±0.211
SHEG (l/mmol) 0.108±0.064 0.085±0.062
CLI (l/kg/min) 0.023±0.014 0.025±0.011
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Figure 7.18: HEb (a), HEtot (b), S
HE
G (C) and CLI (d) indexes: correlation
between the identification in "0÷ 360 min" and "0÷ 300 min".
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Conclusions
Glucose metabolism is regulated by a complex control system, which, in
healthy subjects, maintains plasma glucose concentration within a narrow
range, in order to avoid hypoglycemia or hyperglycemia.
The liver plays an important role in glucose regulation, since, besides produ-
cing glucose, it is also responsible for regulating insulin levels, by extracting a
significant portion of the insulin appearing in the portal vein (approximately
50%) [12], during first pass transit. Therefore, the quantification of HE, in
basal as well as in dynamic conditions, is an essential step to understand the
overall glucose metabolism.
Since direct measurement of HE in humans is very invasive, requiring cath-
eter insertion in the portal and hepatic veins, the only effective method for
assessing HE is the use of mathematical models, that utilize the measure-
ments of plasma insulin, glucose and C-peptide concentrations. Indeed, at
the base of these models, there is the known concept that C-peptide and in-
sulin are equimolarly secreted, but only insulin is extracted by the liver; this
fact allows conception of models which describe insulin, and thus C-peptide,
secretion, and kinetics, including HE.
Toffolo et al. [50] assessed HE during an IM-IVGTT, using a model
of C-peptide secretion and kinetics, previously developed in [10] and [24],
respectively, where C-peptide parameters were fixed according to [55], and
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single-compartment insulin kinetics, in which the parameters could be es-
timated from an insulin infusion. In order to extend this approach to a
meal test, Campioni et al. [11] developed a Model of Data. Since both C-
peptide and insulin kinetic parameters were there fixed, according to [55] and
[11], respectively, HE was described as a piecewise linear function with seven
breakpoints; the values of HE were parameters to be estimated by fitting the
model to insulin data. This approach certainly allows the HE parameters
to obtain a good fit of meal insulin data. On the other hand, the HE for-
mulation does not have a physiological or mechanistic meaning which makes
the model vulnerable to noise, since it can follow rapid peripheral insulin
fluctuations.
In order to improve HE assessment, the aim of this thesis is to propose
a model which contains a broader description of insulin kinetics, and a more
physiological expression of HE. Therefore, the single- [11], two- [17, 26], and
three- [17, 26] compartment insulin kinetic models were tested, coupled with
the new HE descriptions, depending on plasma glucose and insulin concen-
trations, alone and in combination. In so doing, seven new models were
developed, and compared to the Model of Data, proposed by Campioni et al.
According to the results, the best performing model was Model VI, which
describes insulin kinetics with three compartments, and assumes that HE
depends on glucose concentration.
The new model has a concrete physiological meaning: it describes insulin kin-
etics through liver, plasma and extravascular spaces, according to previous
studies conducted first in dogs and then in humans [25, 26, 47]. Moreover,
HE is a function of plasma glucose, supporting the nutrient intake influence
on HE, and, especially, the HE reduction due to hyperglycemia [20, 31, 42].
The new model was first assessed in database 1, the same one adopted
by Campioni et al., made up of 204 healthy subjects, that underwent a
FS-MTT. Besides showing good performance in terms of data prediction
and parameter estimates, it offers many advantages, with respect to the
model available in the literature. First of all, it can well estimate all the
insulin kinetic parameters, differently from the Model of Data, in which they
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were fixed to standard population values. Secondly, it describes HE using a
single parameter, thus overcoming one of the main limitations of the model
developed by Campioni et al., where the HE profile was allowed to rapidly
change due to peripheral insulin fluctuations, making the model vulnerable
to noise. Finally, the new HE formulation allows derivation of a new index,
accounting for HE sensitivity to glucose, i.e. SHEG ; this index was found to
be lower in elderly vs. young (p < 0.05) and this agrees with the knowledge
that glucose control system is impaired in elderly people.
It is of note that this model was originally proposed in a particular frequently
sampled meal time grid (FS-MTT) [6], that is not so easily reproducible in
a usual experimental setting, because of high costs; however, the model has
been shown to perform well even with standard sampling (SS-MTT) [10],
providing precise parameter estimates, and well correlated HE indexes (p <
0.005) between FS- and SS-MTT.
Once the model was assessed in healthy conditions, we used it in all the
spectrum of glucose tolerance (healthy, prediabetic and T2DM subjects), and
also during a different oral challenge, i.e. the OGTT.
The model employment in database 2, made up of prediabetic subjects with
different levels of glucose intolerance, during the MTT, was successful, since
the model could adequately fit the data and estimate the parameters; moreover,
HE indexes (HEb and HEtot) are lower in IFG/IGT than NGT subjects
(p<0.05), thus confirming the knowledge that HE is impaired in conditions
of glucose intolerance.
Having also the OGTT data of the same database, it was interesting to real-
ize that the model performances were good, too, underlying that the effects
of nutrient intake on HE may be different among healthy and prediabetics.
Then, the model was used in database 3, made up of T2DM and healthy
people, who underwent a MTT; the data were well fitted in both the groups,
and the parameters were precisely estimated, even if the T2DM CV were a
little bit higher. In this case, all the HE indexes (HEb, HEtot and SHEG ) were
significantly lower (p<0.05) in T2DM subjects, supporting the awareness of
lower HE in pathological conditions.
Finally, the model was used in database 4, composed of T2DM subjects,
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treated with placebo and vildagliptin, who underwent a particular MTT,
characterized by a 5-min square wave insulin infusion, which should allow a
better estimation of insulin kinetics. In this case, two different identifications
were performed: the first one ("0÷360 min"), by considering the entire pro-
tocol samples, and the second one ("0÷300 min"), by neglecting the insulin
infusion. In both the identifications, no HE difference was revealed among
the placebo and vildagliptin treatments, thus confirming what was previ-
ously found [16]. Interestingly, all the HE indexes, and the insulin clearance
rate, showed a significant correlation between the "0÷300" and "0÷360" min
identification; this result is very important for the proposed model, since it
means there is no need to add an insulin infusion to the experiment in order
to estimate reliable HE indexes.
In conclusion, the present study demonstrates that the HE model pro-
posed by Campioni et al., which currently predicts data well, can be improved
by adopting a three-compartment model for the description of insulin kin-
etics, and by substituting the piecewise linear function with a simple linear
expression which links HE to plasma glucose concentration.
The new model can well describe insulin and C-peptide data during both
MTT and OGTT, in all the spectrum of glucose tolerance, with the peculiar-
ity of providing a new index of HE sensitivity to glucose, which has potential
to help in distinguishing different levels of pathology.
Future developments would be the introduction of this new model in the meal
simulation model of the glucose-insulin system [17], replacing the pre-existent
two-compartment insulin kinetics, and the linear relationship that links HE
to insulin secretion, which suffers from some limitations when predicting HE
in a given individual. Further studies will be required to assess the validity
of this model during different tests, e.g. IM-IVGTT.
Bibliography
[1] Akiyama H., Yokono K., Shii K., Ogawa W., Taniguchi H.,
Baba S., Kasuga M., Natural regulatory mechanisms of insulin de-
gradation by insulin degrading enzyme, Biochem Biophys Res Commun
170: 1325-1330, 1990.
[2] Aronoff S.L., Berkowitz K., Shreiner B., Want L., Glucose meta-
bolism and regulation: beyond insulin and glucagon, Diabetes Spectrum
17(3): 183-190, 2004.
[3] Backer J.M., Kahn C.R., White M.F., The dissociation and de-
gradation of internalized insulin occur in the endosomes of rat hep-
atoma cells, J Biol Chem 265: 14828-14835, 1990.
[4] Basu A., Dalla Man C., Basu R., Toffolo G., Cobelli C., Rizza
R.A., Effects of type 2 diabetes on insulin secretion, insulin action,
glucose effectiveness, and postprandial glucose metabolism, Diabetes
Care 32(5): 866-872, 2009.
[5] Basu R., Di Camillo B., Toffolo G., Basu A., Shah P., Vella
A., Rizza R.A., Cobelli C., Use of a novel triple-tracer approach
to assess postprandial glucose metabolism, Am J Physiol Endocrinol
Metab 284: E55-E69, 2003.
84 Bibliography
[6] Basu R., Dalla Man C., Campioni M., Basu A., Klee G., Tof-
folo G., Cobelli C., Rizza R.A., Effects of age and sex on post-
prandial glucose metabolism: differences in glucose turnover, insulin
secretion, insulin action, and hepatic insulin extraction, Diabetes 55:
2001-2014, 2006.
[7] Bellu G., Saccomani M.P., Audoly S., D'Angiò L., DAISY: A
new software tool to test global identifiability of biological and physiolo-
gical systems, Comput Methods Programs Biomed 88(1): 52-61, 2007.
[8] Bock G., Dalla Man C., Campioni M., Chittilapilly E., Basu
R., Toffolo G., Cobelli C., Rizza R.A., Mechanisms of fasting and
postprandial hyperglycemia in people with impaired fasting glucose
and/or impaired glucose tolerance, Diabetes 55: 3536-3529, 2006.
[9] Bock G., Dalla Man C., Campioni M., Chittilapilly E., Basu
R., Toffolo G., Cobelli C., Rizza R.A., Effects of nonglucose nu-
trients on insulin secretion and action in people with pre-diabetes, Dia-
betes 56(4): 1113-1119, 2007.
[10] Breda E., Cavaghan M.K., Toffolo G., Polonsky K.S., Cobelli
C., Oral glucose tolerance test minimal model indexes of beta-cell func-
tion and insulin sensitivity, Diabetes 50: 150-158, 2001.
[11] Campioni M., Toffolo G., Basu R., Rizza R.A., Cobelli C.,
Minimal model assessment of hepatic insulin extraction during an oral
test from standard insulin kinetics parameters, Am J Physiol Endo-
crinol Metab 297: E941-E948, 2009.
[12] Caumo A., Florea I., Luzi L., Effect of variable hepatic insulin
clearance on the postprandial insulin profile: insights from a model
simulation study, Acta Diabetol 44: 23-29, 2007.
[13] Cobelli C., Carson E., Introduction to modeling in physiology and
medicine, Academic Press, San Diego, 2008.
Bibliography 85
[14] Cobelli C., Pacini G., Insulin secretion and hepatic extraction in
humans by minimal modeling of C-peptide and insulin data, Diabetes
37: 223-231, 1988.
[15] Cobelli C., Toffolo G.M., Dalla Man C., Campioni M., Denti
P., Caumo A., Butler P.C., Rizza R.A., Assessment of β-cell
function in humans, simultaneously with insulin sensitivity and hep-
atic extraction, from intravenous and oral glucose test, Am J Physiol
Endocrinol Metab 293: E1-E15, 2007.
[16] Dalla Man C., Bock G., Giesler P.D., Serra D.B., Saylan M.L.,
Foley J.E., Camilleri M., Toffolo G., Cobelli C., Rizza R.A.,
Vella A., Dipeptidyl peptidase-4 inhibition by vildagliptin and the
effect on insulin secretion and action in response to meal ingestion in
type 2 diabetes, Diabetes Care 32(1): 14-18, 2009.
[17] Dalla Man C., Rizza R.A., Cobelli C., Meal simulation model of
the glucose-insulin system., IEEE Trans on Biomed Eng 54(10): 1740-
1749, 2007.
[18] www.diabetes.org
[19] Dinneen S.F., Maldonado D. 3rd, Leibson C.L., Klee G.G.,
Li H., Melton L.J. 3rd, Rizza R.A., Effects of changing diagnostic
criteria on the risk of developing diabetes, Diabetes Care 21: 1408-1413,
1998.
[20] Duckworth C.W., Insulin degradation: mechanisms, products and
significance, Endoc Rev 2: 210-233, 1988.
[21] Duckworth W.C., Bennet G.B., Hamel F.G., Insulin degrada-
tion: progress and potential, Endocr Rev 19(5): 608-624, 1998.
[22] Duckworth W.C., Runyan K., Wright R.K., Halban P.A., So-
lomon S.S., Insulin degradation by hepatocytes in primary colture,
Endocrinology 108: 1142-1147, 1981.
86 Bibliography
[23] www.easd.org
[24] Eaton R.P., Allen R.C., Schade D.S., Erickson K.M.,
Standefer J., Prehepatic insulin production in man: kinetic ana-
lysis using peripheral connecting peptide behaviour, J Clin Endocrinol
Metab 51: 520-528, 1980.
[25] Ellmerer M., Hamilton-Wessler M., Kim S.P., Dea M.K.,
Kirkman E., Perianayagam A., Markussen J., Bergman R.N.,
Mechanism of Action in Dogs of Slow-Acting Insulin Analog O346, J
Endocrinol Metab 88(5): 2256-2262, 2003.
[26] Ferrannini E., Cobelli C., The kinetics of insulin in man. II. Role
of the liver, Diabetes Metab Rev 3: 365-397, 1987.
[27] Greenway C.V., Stark R.D., Hepatic vascular bed, Physiol Rev
51(1): 23-65, 1971.
[28] Hamel F.G., Mahoney M.J., Duckworth W.C., Degradation of
intraendosomal insulin by insulin degrading enzyme without acidifica-
tion, Diabetes 40: 436-433, 1991.
[29] Hamel F.G., Peavy D.E., Ryan M.P., Duckworth WC., High
performance liquid chromatographic analysis of insulin degradation
products from isolated hepatocytes: effects of hinibitors suggest in-
tracellular and extracellular pathways, Diabetes 36: 702-708, 1987.
[30] Harada S., Smith R.M., Smith J.A., Shah N., Jarett L.,
Demonstration of specific insulin binding to cytosolic proteins in H35
hepatoma cells, rat liver, and skeletal muscle, Biochem J 306: 21-28,
1995.
[31] Hennes M.M., Dua A., Kissebah A.H., Effects of free fatty acids
and glucose on spalachnic insulin dynamics, Diabetes 46: 57-62, 1997.
[32] Hennes M.M., Shrago E., Kissebah A.H., Mechanism of free fatty
acid effects on hepatocyte insulin receptor binding and processing, Obes
Res 1(1): 18-28, 1993.
Bibliography 87
[33] www.idf.org
[34] Jensen M.D., Kanaley J.A., Reed J.E., Sheedy P.F., Measure-
ment of abdominal and visceral fat with computed tomography and
dual-energy x-ray absorptiometry, Am J Clin Nutr 61: 274-278, 1995.
[35] Jochen A., Hays J., Lee M., Kinetics of insulin internalization and
processing in adipocytes: effects of insulin concentration, J Cell Physiol
141: 527-534, 1989.
[36] Kuo W.L., Gehm B.D., Rosner M.R., Regulation of insulin de-
gradation: expression of an evolutionary conserved insulin-degrading
enzyme increases degradation via an intracellular pathway, Mol Endo-
crinol 5: 1467-1476, 1991.
[37] LeRoith D., Taylor S.I., Olefsky J.M., Diabetes mellitus: a fun-
damental and clinical text, 3rd edition, Lippincott Williams & Wilkins,
2004.
[38] Levy J., Olefsky J.M., The effects of insulin concentration on ret-
roendocytosis in isolated rat adipocytes, Endocrinology 120: 450-456,
1987.
[39] Meier J.J., Veldhuis J.D., Butler P.C., Pulsatile insulin secretion
dictates systemic insulin delivery by regulating hepatic insulin extrac-
tion in humans, Diabetes 54(6): 1649-1656, 2005.
[40] Meigs J.B., Muller D.C., Nathan D.M., Blake D.R., Andres
R., The natural history of progression from normal glucose tolerance to
type 2 diabetes in the Baltimore Longitudinal Study of Aging, Diabetes
52: 1475-1484, 2003.
[41] Pagano C., Rizzato M., Lombardi A.M., Fabris R., Favaro
A., Federspil G., Vettor R., Effect of lactate on hepatic insulin
clearance in perfused rat liver, Am J Physiol 270: R682-R687, 1996.
88 Bibliography
[42] Pivovarova O., Gogebakan O., Pfeiffer A.F.H., Rudovich N.,
Glucose inhibits the insulin-induced activation of the insulin-degrading
enzyme in HepG2 cells, Diabetologia 52: 1656-1664, 2009.
[43] Seabright P.J., Smith G.D., The characterization of endosomal in-
sulin degradation intermediates and their sequence of production, Bio-
chem J 320: 947-956, 1996.
[44] Sherwin R.S., Kramer K.J., Tobin J.D., Insel P.A., Liljenquist
J.E., Berman M., Andres R., A model of the kinetics of insulin in
man, J Clin Invest 52: 1481-1492, 1974.
[45] Smith R.M., Jarret L., Biology of disease. Receptor-mediated endo-
cytosis and intracellular processing of insulin: ultrastructural and bio-
chemical evidence for cell-specific heterogeneity and distinction from
nonhormonal ligands, In Rubin E., Damjanov I. (eds) Pathology re-
views. Humana Press Inc., Clifton, NJ 37-53, 1989.
[46] Sonne O., Receptor-mediated endocytosis and degradation of insulin,
Physiol Rev 68(4): 1129-1195, 1988.
[47] Steil G.M., Ader M., Moore D.M., Rebrin K., Bergman R.N.,
Transendothelial insulin transport is not saturable in vivo, J Clin Invest
97(6): 1947-1503, 1996.
[48] Surmacz C.A., Wert J.J., Ward W.F., Mortimore G.E., Uptake
and intracellular fate of [14C]sucrose-insulin in perfused rat livers, Am
J Physiol 255: C70-C75, 1988.
[49] Svederg J., Bjorntorp P., Smith U., Lonnroth P., Free fatty
acids inhibition of insulin binding, degradation, and action in isolated
rat hepatocytes, Diabetes 39: 570-574, 1996.
[50] Toffolo G., Campioni M., Basu R., Rizza R.A., Cobelli C., A
minimal model of insulin secretion and kinetics to assess hepatic insulin
extraction, Am J Physiol Endocrinol Metab 290: E169-E176, 2006.
Bibliography 89
[51] Toffolo G., Cefalu W., Cobelli C., Beta-cell function during insulin
modified IVGTT successfully assessed by the C-peptide minimal model,
Metabolism 48: 1162-1166, 1999.
[52] Toffolo G., De Grandi F., Cobelli C., Estimation of beta-cell sens-
itivity from IVGTT C-peptide data. Knowledge of the kinetics avoids
errors in modeling the secretion, Diabetes 44: 845-854, 1995.
[53] Tura A., Ludvik B., Nolan J.J., Pacini G., Thomaseth K.,
Insulin and C-peptide secretion and kinetics in humans: direct and
model-based measurements during OGTT, Am J Physiol Endocrinol
Metab 281: E966-E974, 2001.
[54] Tirosh A., Shai I., Tekes-Manova D., Israeli E., Pereg D.,
Shochat T., Kochba I., Rudich A., the Israeli Diabetes Re-
search Group, Normal fasting plasma glucose levels and type 2 dia-
betes in young men, N Engl J Med 353: 1454-1462, 2005.
[55] Van Cauter E., Mestrez F., Sturie J., Polonsky K.S., Estim-
ation of insulin secretion rates from C-peptide levels. Comparison of
individual and standard kinetic parameters for C-peptide clearance,
Diabetes 41: 368-377, 1992.
[56] Volund A., Polonsky K.S., Bergman R.N., Calculated pattern
of intraportal insulin appearance without independent assessment of
Cpeptide kinetics, Diabetes 36: 1195-1202, 1987.
[57] Wiesenthal S.R., Sandhu H., McCall R.H., Tchipashvili V.,
Yoshii H., Polonsky K.S., Shi Z.Q., Lewis G.F., Mari A.,
Giacca A., Free fatty acids impair hepatic insulin extraction in vivo,
Erratum appears in Diabetes 48(4): 766-774, 1999.
[58] Yonezawa K., Yokono K., Shii K., Hari J., Yaso S., Amano
K., Sakamoto T., Kawase Y., Akiyama H., Nagata M., Baba
S., Insulin-degrading enzyme is capable of degrading receptor-bound
insulin , Biochem Biophys Res Commun 150: 605-614, 1988.

Acknowledgments
I want to thank Prof. Chiara Dalla Man and Prof. Claudio Cobelli,
that both supervised my research work with their constructive suggestions
through all these years, and taught me the importance of being independent
and hard-working.
I would also like to thank Dr. Adrian Vella, my "abroad advisor", for al-
lowing me to spend a period at Mayo Clinic, working with his extraordinary
team; the months I spent collaborating with him in Rochester represent an
important research and personal experience, that I will pleasantly remember
forever. I need to thank Dr. Adrian Vella also for his constant "distance
support", since he has always helped me, even when I came back to Padova.
Thanks to all the friends I met in the bioengineering Ph.D. group, for the
funny time we spent together, and for the help they have always given
me, especially Chiara, Francesca, Michela, Fabio, Mattia, Anna, Federica,
Emanuele and Michele.
Thanks to Giacomo, for being my first supporter, and for always reminding
me of my capabilities and qualities.
Grazie a mia mamma, per tutte le volte che mi ha supportata e appoggiata
nelle le mie scelte, credendo sempre in me.
